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ABSTRACT OF THE DISSERTATION

The Effects of Long Term Walnut Consumption on Levels of Plasma Tocopherols and
Inflammatory Mediators
by
Suwimol Sapwarobol
Doctor of Pubic Health in Nutrition
Loma Linda University, Loma Linda California, 2005
Ella H. Haddad, Chairman

The purpose of this study was to determine the effects of long term walnut
consumption on plasma levels of tocopherols and the inflammatory mediators
interleukin-1(3 (IL-1(3), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a) and Creactive protein (CRP) in healthy participants. Ninety participants were recruited into a
12-month randomized crossover intervention study, which consisted of two phases, the
walnut supplemented diet and the habitual diet. Participants were randomly assigned to
either of these two phases for six months and then switched to the other phase for the
second six months. During the walnut supplemented diet phase, participants incorporated
walnuts (28-56 g/d) equal to 12% of their daily energy intake into their habitual diet.
Plasma concentrations of a-tocopherols were significantly decreased but y-tocopherol
level was insignificantly increased during walnut supplemented diet. However, the ratio

iii

of y-tocopherol to cholesterol was significantly higher on the walnut supplemented diet.
In addition, data from preliminary analysis on correlation of gender, age and BMI on
CRP showed linear effect of BMI to log (CRP) (|3 = 0.088 ± 0.029, p = 0.002), however,
no effect of gender and age on CRP levels were found. CRP levels were almost 50%
lower in the group of NSAIDs and vitamin E supplement users. Moreover, the walnuts
supplemented diet together with vitamin E supplement elevated CRP level by 22.72%.
After excluding usage of fish oil, vitamin E supplement and NSAIDs, thirty participants
were qualified for the inflammatory mediator analysis. There was no significant change
in any of the plasma e-selectin and TNF-a level. However, IL-ip and IL-6 were
significantly decreased during the walnuts supplemented diet (p < 0.05). In conclusion,
the addition of walnuts for 12% of daily energy intake into the diet did not increase
plasma y-tocopherol, but decreased a-tocopherol level significantly. Moreover, IL-1 (3 and
IL-6 were decreased significantly with this amount of walnuts intake.
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CHAPTER 1
INTRODUCTION
A. Statement of the Problem
The importance of including walnuts (Juglans regia) in a healthful diet is widely
acknowledged. According to prospective cohort studies such as the Adventist Health
Study (Fraser et ah, 1992), the Nurses Health Study (Hu et ah, 1998), the Iowa Woman’s
Health Study (Kushi et ah, 1996) and the Physician’s Health Study (Morgan et ah, 2002),
more frequent nut consumption is correlated with cardiovascular risk reduction and is
inversely associated with all cause mortality. Clinical human intervention studies which
involve adding walnuts to the diet are consistent in showing decreases in total cholesterol
and Low Density Lipoprotein (LDL)-cholesterol (Sabate et al., 1993; Abbey et al., 1994;
Chilsholm et al., 1998; Zambon et al., 2000; Almario et al, 2001). The favorable
metabolic outcomes of consuming walnuts is thought to be due to a lipid composition low
in saturated fatty acids (SFA) and high in polyunsaturated fatty acids (PUFA). Although
the nutrient contribution of walnuts is similar to that of other tree nuts, it is distinguished
by a high proportion of the n-3 fatty acids, oc-linolenic acid and of y-tocopherol.
Beneficial health effects of n-3 fatty acids have received considerable interest
ever since it was reported that coronary atherosclerosis is almost unknown among
Greenland Eskimos living in their original cultural environment and consuming primarily
a fish diet rich in n-3 fatty acids as compared to those living in Denmark. The n-3 fatty
acids have a wide range of physiological effects. Those relevant to heart disease are
influences on blood lipids, endothelial function and cytokine production.
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Studies have shown that long term supplementation of capsules from fish oil
containing the long chain n-3 fatty acids eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) reduced production of proinflammatory mediators such as
interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor (TNF) in healthy
volunteers (Endres et al., 1989; Calder 1997; Kew et ah, 2003; Venkatraman et ah, 1999).
The inhibition of IL-1, IL-6 and TNF production is accompanied by a decreased ratio of
arachidonic acid (AA) to EPA in the membrane phospholipids of mononuclear cells
(Endres et al., 1989). EPA can be formed endogenously from the 18-carbon fatty acid alinolenic acid (18:3,n-3). Flaxseed oil, which contains a high proportion of ot-linolenic
acid, inhibited TNF-a and IL-lp production to a lesser extent -30% compared to a >70%
inhibition achieved using concentrated fish oil capsules (Caughey et al., 1996). The effect
of walnut lipids on proinflammatory mediator synthesis has not been examnined.
In addition to n-3 PUFA, walnuts are a rich source of y-tocopherol, which may
also have a role in inflammatory response. The tocopherols including y-tocopherol are
antioxidant scavenging compounds known to inhibit phospholipid oxidation and the
oxidation of LDL components. Conditions associated with increased intracellular
oxidative stress facilitate nuclear translocation of the transcriptional factor Nuclear Factor
(NF)-kB and induce the production of proinflammatory cytokines (Flohe et al., 1997;
Asehnoune et al., 2004). Studies have shown that oc-tocopherol supplementation inhibits
NF-kB activation and inflammation in vivo (Devaraj et al., 1996; Blackwell et al., 1996).
More recently Li et al (1999) showed that treatment of human coronary artery endothelial
cells with y-tocopherol attenuated the oxidized-LDL mediated activation of NF-kB. It is
2

not known whether the addition of walnuts to the diet would increase blood levels of ytocopherol and inhibit the inflammatory response by protecting cells from oxidative
challenge.
Besides the inflammatory cytokines, C-reactive protein (CRP) has also been
investigated in coronary vascular disease (CVD). As an acute phase reactant, CRP is a
non-specific marker of inflammation. Evidence suggested that CRP may have a direct
proinflammatory effect involved in CVD (Wadham et al., 2004). CRP was consistently
shown to be a strong predictor of CVD (Ridker et al., 1998; Ridker et al., 2002).
Research suggests that protective effect of nuts in the diet is due to their lipid
lowering potential. However, nuts also contain substantial amounts of tocopherols and
some nuts, especially walnuts, are rich sources of a-linolenic acid. According to
Continuing Survey of Food Intakes by Individuals, CDFII (1994-96) current US dietary
intake of linoleic acids (18:2, n-6) to a-linolenic acid (18:3, n-3) is 9.5:1, whereas a
current recommendation is a ratio of 5:1. Marine sources of n-3 fatty acids are
problematic to some due to concentrations of environmental contaminants. The long-term
safety of flaxseed and flaxseed oil consumption has not been established. Walnuts,
however, have been an important ingredient in cultural diets of Mediterranean countries
for centuries. There is as yet no information regarding the association between walnuts
ingestion, antioxidant status and proinflammatory cytokines production. It remains to be
determined whether the addition of walnuts to the diet produces similar effects on
reduction of proinflammatory mediators and cytokines as those observed in fish and
flaxseed oil via enhancing antioxidant status.
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B. Purpose of the Study
The purpose of this study is to further explore the role of nuts in the diet beyond
that of blood lipids. More specificially, it is to determine whether the addition of walnuts
to the habitual diet influences markers of antioxidant and the inflammatory response in
healthy free-living adults. Reduced oxidative stress and inflammation may explain some
of the positive health outcomes associated with walnuts consumption.
C. Objective
Specifically, the objective of this study is to examine the effect of incorporating
walnuts into diets on plasma markers of: (1) antioxidant status assessed by measuring
levels of a-, P-, y-, and 8- tocopherol; and (2) inflammation assessed by measuring levels
of the proinflammatory cytokines IL-lp, IL-6, TNF-a and CRP. The study will also seek
to determine the correlation between tocopherols and inflammatory mediators.
D. Research Questions
The study will focus on the following research questions:
(1)

How does daily walnut consumption influence the levels of plasma
tocopherols?

(2)

How does daily walnut consumption influence proinflammatory
cytokines and CRP production?

(3)

Is there any correlation between levels of plasma tocopherols after
walnuts consumption and proinflammatory cytokines in healthy
people?

4

CHAPTER 2
REVIEW OF THE LITERATURE
A. Introduction
The concept that natural foods, or their components, offer benefits beyond basic
nutrition is relatively new to the scientific community. This knowledge continues to be
supported by research, which demonstrates that a health promoting diet is defined as
much by foods consumed as by those avoided.
Epidemiologic evidence for the protective action of nut consumption in heart
disease prevention was first observed by Fraser, Sabate and colleagues in the Adventist
Health Study cohort. This association was strengthened as evidence emerged from
various observational and intervention studies on nuts.
Walnuts (Juglans regia L.) are traditional nuts in diets of the Mediterranean
region, South America and Asia. They are one of the ancient tree foods known to
humans. Although nuts are included in the USDA’s Food Guide Pyramid as part of the
“Meat, Dry Beans, Eggs and Nuts” group, the per capita consumption of nuts is relatively
low in the United States (US) as compared to other countries. Due to their caloric density
and high fat content, walnuts were not commonly considered to be an integral component
of a healthy diet, however, this concept is changing.
Walnuts contain numerous beneficial nutritive and bioactive compounds
including polyunsaturated fatty acids, dietary fiber, trace minerals and phytochemicals,
many of which may be cardioprotective (Table 1). Walnuts are a rich source of
tocopherols, especially y-tocopherol, which may be an important anti-atherogenic agent.
(Spiller et al., 1998; Ros et al., 2004; Zambon et al., 2000; Almario 2001)
5

Table 1. Nutrient Composition of Walnuts
Nutrient

Units

Energy
Protein
Total lipid (fat)
Dietary fiber
Calcium, Ca
Iron, Fe
Magnesium, Mg
Phosphorus, P
Potassium, K
Sodium, Na
Vitamin A
Thiamin
Riboflavin
Ascorbic acid
Niacin
Pantothenic acid
Folate
Alpha-tocopherol
Beta-tocopherol
Gamma-tocopherol
Delta-tocopherol
Fatty acids, total saturated
16:0
18:0
20:0
Fatty acids, total monounsaturated
18:1 undifferentiated
20:1
Fatty acids, total polyunsaturated
18:2 undifferentiated
18:3 undifferentiated
Phytosterols
US. Department of Agriculture

Kcal
G
G
G

Mg
Mg
Mg
Mg
Mg
Mg
IU
Mg
Mg
Mg
Mg
Mg
Meg
Mg
Mg
Mg
Mg
G
G
G
G
G
G
G
G
G
G

Mg

6

Value per 100 g of
edible portion
654
15.23
65.21
6.7
98
2.91
158
346
441
2
20

0.341
0.150
1.3
1.125
0.570
98
0.70

0.15
20.83
1.89
6.126
4.404

1.659
0.063
8.933
8.799
0.134
47.174
38.093
9.080
72

As shown above, walnuts are a rich source of both a-linolenic acid (ALA), an n-3
fatty acid (9.1 g/100 g edible portion) and linoleic acid (LA), an n-6 fatty acid (38.1
g/lOOg edible portion). According to the above table, the ratio of linoleic to a-linolenic
acid (4.2:1) in walnuts is the ratio that has been recommended.
The Continuing Survey of Food Intakes by Individuals 1994-1996 (CSFII 19941996) stated that current US dietary intake of linoleic acid to a-linolenic acid is 9.5:1
whereas the recommended ratio is 5:1. Thus, the addition of walnuts into the diet is the
simple and uncomplicated way expected to move the ratio of linoleic acid to a-linolenic
acid closer to the ideal.
The purpose of this literature review is two-fold. First, it is to summarize
outcomes reported in published studies on the effects of long term incorporation of
walnuts into the habitual diet. Second, it is to discuss other potential health benefits of
walnuts which are expected based on their unique nutrient contents and non-nutrient
composition.
B. Studies on Walnut Consumption
1. Observational Studies
Up to date, dietary alteration is believed to be a highly cost-effective
method for cardiovascular disease (CVD) prevention. A number of studies have
identified several dietary determinants of coronary heart disease (CHD), including
specific type of fat, folate, vitamins, dietary fiber and moderate alcohol consumption.
Recently, a number of observational studies on the association of nut consumption and
CHD risk reduction have been published. They consistently suggest that frequent nut
consumption may be protective against CHD.
7

Nuts are complex plant foods that are not only rich sources of unsaturated fat but
also contain several non-fat constituents such as plant protein, fiber, micronutrients, plant
sterols and phytochemicals. However, the consumption of nuts in the United State has
been declining since the mid-1980s, because of the concern with their high-fat content.
Four prospective cohort studies, namely the Adventist Health Study, the Iowa
Woman Health Study, the Nurses Health Study, and the Physician’s Health Study, have
consistently shown the health benefits of nuts consumption on the prevention of heart
disease.
The protective effect of nuts on CHD morbidity and mortality was first suggested
by data from the Adventist Health Study, a large prospective cohort investigation of
31,208 non-Hispanic white Seventh-day Adventists in California. (Fraser et al., 1992).
After 6 years follow up, subjects were evaluated for first event myocardial infarction
(MI), or CHD. The finding suggested that people who consumed nuts 1-4 times per week
had a 22% reduced risk of MI compared to those that consumed nuts less than once a
week. Moreover, people who consumed nuts four times a week or more experienced
fewer fatal CHD events (relative risk 0.52; 95% confidence interval, 0.36 to 0.76) and
nonfatal MI (relative risk, 0.49; 95% confidence interval, 0.28 to 0.85) when compared to
those who consumed nuts less than one time a week.
Subsequent analysis of data from the Adventist Health Study (Fraser et al., 1995;
Fraser 1999; Sabate, 1999) showed that the protective effect of nut consumption on CHD
was consistent in both men and women, in younger and older individuals, and in people
with normal and high blood pressure. Furthermore, the same protective effect on CHD
was demonstrated in people regardless of their relative weight, smoking status, or
8

physical activity level. When assessing lifetime risk of developing CHD and age at first
coronary event, Fraser et al. (1995) estimated that people who consumed nuts more than
5 times per week had a 12% lower lifetime risk of heart disease. Additionally, among
men who experienced CHD those that consumed walnuts had the event 5.6 years later
than did men who consumed nuts infrequently.
The Iowa Women’s Health Study is a prospective cohort study that followed
34,486 postmenopausal women for a total of 7 years to determine the effect of long term
nut consumption on CHD mortality (Kushi et al., 1996). Over the 5 years follow up, 154
women who had been free of CHD at the baseline died of CHD. The CHD mortality was
inversely associated with nuts intake. Over the total of 7 years follow up, 242 women
died of CHD. In this study, multivariate analysis of the association between risk of death
from CHD and intake of specific foods in women who did not take supplements showed
a relative risk of 0.60 (95% confidence interval 0.35-1.01) in those who consumed nuts
and seeds more than 4 times a month compared to those who never consumed nuts.
Another epidemiologic support of association between nut consumption and heart
disease comes from the Nurses Health Study (Hu. et al., 1998; Hu et al., 1999) which
focused on the association between nut consumption and nonfatal MI. Participants of this
study were 86,016 female registered nurses aged 34 - 59 y. residing in 11 large US states.
This study had shown that nurses who consumed at least 5 oz. of nuts per week had a
35% lowering in nonfatal MI compared to those eating less than 1 oz. of nuts per month.
In this study 1255 cases of major coronary disease events were documented during 14
years of follow-up. Results after adjusting for age, smoking, and other known risk factors
for coronary heart disease demonstrate that women who ate more than 5 oz (140 g) of
9

nuts a week had a significantly lower risk of CHD (relative risk 0.65, 95% confidence
interval 0.47 to 0.89) than women who never ate nuts or who ate less than 1 oz (28 g) a
month.
In the Physician’s Health Study (Albert et al., 1998) 21,454 male physician
participants were followed prospectively for 17 years to examine the association between
nut consumption and risk of sudden death and total cardiac death. After controlling for
known cardiac risk factors, dietary nut intake was associated with a significantly reduced
risk of sudden cardiac death. Compared with men who rarely or never consumed nuts,
those who consumed nuts 2 or more times per week had reduced risk of sudden cardiac
death (RR= 0.53; 95% CI= 0.30-0.92) and total CHD mortality (RR= 0.70; 95% Cl =
0.50-0.98). In this study nut intake was not associated with reduced risk of nonsudden
CHD or nonfatal MI. The investigators suggested that as nut consumption increased the
risk for cardiac and sudden cardiac deaths decreased significantly.
In summary, four large prospective cohort studies have agreed that the frequency
of nut consumption seems to be inversely related to the risk of CHD. These beneficial
effects are similar in males and females, and the young and the elderly.
2. Clinical Intervention Studies
The epidemiologic evidence indicating an inverse association between
consumption of nuts and risk of CHD provided the impetus for intervention trials
designed to investigate the mechanisms underlying this effect. These studies assessed the
effect of feeding a single type of nut (pecan, almond, walnut, peanut) either as a
supplement in a field trial or under carefully controlled metabolic conditions.

10

The effects of walnut consumption on biomarkers of atherosclerosis were
evaluated in five controlled studies in primarily healthy and in normal or hyperlipidemic
subjects. These studies are presented here in chronological order of publication.
The first of the nuts to be tested in a controlled feeding study in human was
walnuts. Sabate et al. (1993) studied the effects of walnuts consumption on serum lipids
and blood pressure in 18 free-living healthy, normal weight and normolipidemic adult
males. The participants were randomly placed in a National Cholesterol Education
Program (NCEP)/ American Heart Association (AHA) stepl diet, either with or without
walnuts supplementation at 20% of daily calories. The participants were requested to
follow both diets for four weeks each in a randomized crossover design.
Results have shown that during the walnut supplemented diet, total cholesterol,
low density lipoprotein cholesterol (LDL) and high density lipoprotein cholesterol (HDL)
levels were significantly decreased by 12%, 16% and 5% respectively; all changes were
statistically significant. The investigators concluded that replacing a portion of the fat in a
cholesterol-lowering diet with walnuts produces more favorable lipoprotein profile and
further reduces serum cholesterol level and that the average consumption of walnuts 28 g
per day would lower total-C and LDL-C by 4 and 6% respectively.
Abbey et al. (1994) also examined the effects of nut consumption on blood lipids
profile. This study was conducted on 16 normolipidemic males with a 36% fat diet for 3
weeks period. In this study, the investigators intended to compare three diets: one
enriched with peanuts and coconuts which provided 47 g of both monounsaturated fatty
acids (MUFA) and polyunsaturated fatty acids (PUFA); an almond enriched diet (84 g of
almond per day) which provided mainly MUFA; and, a walnut enriched diet (68 g of
11

walnuts per day) which provided mainly PUFA. Sixteen normalipidemic males were
assigned to follow these three diet regimens for three weeks each. The dietary intake was
monitored and verified by food records, with special emphasis on different type of fat
intake.
After 3 weeks of each diet, the results indicated that both almond and walnut
enriched diets significantly reduced total-C and LDL-C by 6 and 10% respectively. There
was no significant difference in HDL-C and triacylglycerol values among those three
diets. The plasma linoleic and a-linolenic acids were significantly increased. The
investigators suggested that PUFA and MUFA rich nuts should be included in the diets as
a replacement for some of the SFA for favorable health effects.
Chisholm et al. (1998) also studied the effects of walnuts consumption (78 g/day)
on lipid metabolism in 21 males with moderate hypercholesterolemia. Walnuts were
included into the 38% “LF” diet. After 4 weeks follow up, total-C and LDL-C were
decreased by 4 and 8% respectively in the walnut diet compared to baseline. In contrast.
HDL-C was increased significantly by 42% with the walnuts supplemented diet.
Triacylglycerol linolenate also increased significantly. In this study, fatty acid profile of
the major lipid fractions after walnuts ingestion showed changes which might be
expected to reduce risk of cardiovascular disease.
In 2000, Zambon et al., conducted a randomized, crossover feeding study to
determine the effect of different types of fat on blood lipid profiles. This study was
carried out on 49 men and women participants with polygenic hypercholesterolemia. This
study was also designed to assess the acceptability of walnuts and their effects on serum
lipid levels and LDL-oxidizability in free-living hypercholesterolemia patients. In a high
12

PUFA diet, walnuts contributed approximately 18% of the total energy intake and 35% of
the total fat. A high MUFA Mediterranean diet served as control. After 6 months
consumption of each diet, examinations of blood lipid profiles were performed. Walnut
diet produced mean changes of -4.1% in total cholesterol level, -5.9% in LDL, and -6.2%
in lipoprotein(a) level compared to the control diet. In addition, reductions of total
cholesterol and LDL-C by 9 and 11% respectively were observed in the walnut diet.
There was, however, no significant difference in HDL-C or triacylglycerol in the walnuts
supplemented diet compared to control diet. Moreover, during the walnuts supplemented
diet the ability of LDL resistance to oxidative stress was preserved. Investigators
concluded that incorporating walnuts for part of a high MUFA cholesterol-lowering diet
further reduces total cholesterol and LDL-C in subjects with hypercholesterolemia.
In 2001, Almario et al conducted a study to determine the effects of walnut intake
on plasma fatty acids and lipoproteins in patients with combined hyperlipidemia. In this
study, four types of diet were examined: the habitual diet (31% fat) and a low fat diet
(20% fat) and these two diets supplemented with walnuts (48 g). Thirteen males and
females completed the four diets. The results showed that during the walnut
supplemented low fat diet, plasma total cholesterol concentrations decreased by 0.58 ±
0.16 mmol/Lwhen compared with the habitual diet and by 0.46 ± 0.14 mmol/L when
compared with the low fat diet. In addition, the data indicated that incorporating walnuts
(48 g) to a low fat diet decreased total cholesterol and LDL-C by 8 and 12% respectively
when compared with those on the low fat diet alone. HDL-C level, however, decreased
significantly by 10% with this amount of walnuts supplementation. The investigators,
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therefore, noted that the cholesterol-lowering effect caused by adding walnuts to the low
fat diet could be explained by the specific effect of the PUFA and MUFA content.
The findings of these five clinical human intervention studies consistently
demonstrated decrease in total cholesterol and LDL-C levels with consumption of
walnuts two to three servings daily. The main n-3 PUFA in walnuts, a-linolenic acid
(ALA; 18:3n-3), is believed to be the cause of these beneficial health effects of walnuts.
ALA is the essential precursor of n-3 PUFAs [eicosapentaenoic acid (EPA; 20:5 n-3), and
docosahexaenoic acid (DHA; 22:6n-3)] found mostly in fish oils. It could also be
elongated and desaturated in the human body to form long chain PUFA. Therefore, the
effects of walnut on lowering both total cholesterol and LDL-C level as proved in fish
oils are acknowledged. These five studies also proved the potential health benefit of
walnuts in CHD risk reduction. Moreover, these effects have been accomplished whether
walnuts were incorporated in a habitual diet, cholesterol lowering diet step 1, a low fat
diet or a diet already high in PUFA. The effect of walnuts consumption on increasing
HDL-C level, however, was inconsistent in these intervention studies.
Even though there are many proposed biological mechanisms of walnuts intake
on blood lipid profile, the clear biological mechanism remains unclear. Since walnuts are
a rich source of PUFA, the high bioavailability of PUFA in the body after walnuts
consumption is one of the major suggested biological mechanisms. A possible effect of
walnuts on homocysteine also needs to be examined. Similarly, the effect of arginine
contained in walnuts may also be significant but remains unclear.
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C. Potential Health Benefits of Walnut Components
1. Gamma -Tocopherol
Walnuts contain a high concentration of y-tocopherol, which is one of a
group of substances identified more than eighty years ago as factors essential for
reproduction in female rats. Reproductive failure was observed in female rats fed semipurified diets that otherwise contained adequate amounts of vitamins A, B-complex, C
and D, and those other vitamin and minerals that supported growth and general health,
indicating lack of an essential nutrient.
The word tocopherol came from Greek “tokos” mean childbirth, “phorein” mean
to bring forth, and “ol” for the alcohol portion of the molecule. To represent this group of
factors, the term vitamin E was officially accepted in 1925, as the fifth serial alphabetical
designation for vitamins. Vitamin E was formally recognized as an essential nutrient for
humans by inclusion in the Recommended Dietary Allowances (RDA) table of the Food
and Nutrition Broad, National Academy of Sciences in 1968 (Kasparek 1980).
Originally, the term “vitamin E” was the generic name applied to the family of 8
different but structurally related tocopherol and tocotrienol derivatives (chromanols) that
are produced exclusively by plants and that qualitatively exhibit the biologic activity of
a-tocopherol. Four belong to the tocopherol family: a-, p-, y- and 5 -tocopherols; the
other four are tocotrienols: a-, p-, y- and 5- tocotrienol. Structurally, the tocopherols and
tocotrienols differ at their phytyl side chain that tocopherols have a saturated phytyl side
chain with 3 chiral centers that are in an RRR configuration at positions 2, 4', and 8' in
the naturally occurring forms; whereas, tocotrienols have an unsaturated side chain. The
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eight forms of tocopherols are not interconvertible in mammalian and human systems
(Kasparek 1980).
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Figure 1. Structures of the naturally occurring forms of the tocopherols and
tocotrienols
(Kasparek 1980)
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The Food and Nutrition Board at the National Academy of Sciences recently
released updated Dietary Reference Intakes (DRIs) for vitamin E. The committee
recommended DRIs based exclusively on the ct-tocopherol form of vitamin E, because it
is the only form recognized by the a-tocopherol transport protein in the liver,
preferentially secreted into the plasma, and maintained by the body. (Dietary Reference
Intakes, 2000)
a. Gamma-Tocopherol in the Diet and in Walnuts. Even though the
vitamin E requirement is based exclusively on a-tocopherol, the most prevalent and
abundant form of vitamin E in plants is y- tocopherol. As a result, approximately 70% of
the tocopherols consumed in the typical US diet is y-tocopherol. Most of the y-tocopherol
in the diet comes from vegetable oils such as com, soybean, sesame seed, and peanut oils
and their derivative products such as margarine and salad dressings. In contrast, atocopherol is contained mainly in almond, wheat germ and sunflower oil (McLaughlin
1979).
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Table 2. Tocopherols Content in Foods
Dietary
a
Milk
Bread
White
Whole wheat
Fish
Margarine
Seeds and Nuts
Peanuts
Almonds
Sunflower seeds
Walnuts
Oils
Com
Safflower
Wheat germ
Cottonseed

Olive
Coconut

Tocopherols (mg/lQOg)
B
1

5

0.04
0.04

0.02

0.024

0.1

0.16
0.60
11.70

0.15

0.38

0.2

29.00

8.1

0.43

6.60
0.89

0.25

1.30
0.15

20.83

1.89

60.20
17.40
26.00
38.70
0.83
0.20

1.80
24.00
27.1

9.7
25.87
34.50
0.70

13.43
38.7
133.00
38.90
14.35
0.09

5.00
71.00
0.11

US. Department of Agriculture

The tocopherols content of diets may shows great variation depending upon
harvesting, processing, storage and final food preparation procedures.
b. Absorption, Transport and Distribution. The absorption of
tocopherols depends upon factors that are commonly important in lipid digestion and
intestinal uptake. In addition, the degree of absorption varies with total lipid absorption.
The efficacy of the absorption; however, decreases as large amounts of tocopherols are
consumed. In 1972, Losowsky et al. demonstrated that the absorption rate of tocopherols
declined from 60% when 0.04 mg of oc-tocopherol was administered to 30% when 20 mg
were given. In healthy individuals, the absorption rate of 50-70% can be reached for
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dietary levels of a-tocopherol ranging from 0.4 mg to 1 mg. However, the efficacy falls
to less than 10% when pharmacologic doses of 200 mg or more are administered.
The utilization of deuterium-labeled tocopherols has facilitated the understanding
of the absorption and transport of tocopherols (Kayden et al., 1993). Summarization of
current knowledge of the absorption and metabolism of a- and y- tocopherol are shown
below.
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Figure 2. The absorption and transport pathway of a-, and y- tocopherol
(Jiang et al., 2001)
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All forms of tocopherols are taken up without any preference by intestinal cells
after digestion and released into the circulation with chylomicrons. In general, the
quantity absorbed varies depending on the amount of the lipid present (Kayden et ah,
1993; Traber et al., 1992; Traber et ah, 1989). During chylomicron transport, some of the
tocopherol forms are presumably released to peripheral tissues including brain, lung,
heart, skeleton muscle and adipose tissues with the aid of lipoprotein lipase.
The tocopherols appear to reach the liver by chylomicron remnants. In the liver,
a-tocopherol is preferentially reincorporated into nascent very low density lipoprotein
(VLDL) by a mechanisms linked to a-tocopherol transport protein (a-TTP). Other
tocopherol forms are much less well retained and are oxidized to carboxyethyl
hydroxychromans (CEHC), and excreted via the bile, the urine, or other unknown routes.
Studies have demonstrated a constant fractional rate of a-tocopherol absorption in
healthy individuals. This rate determines a normal a-tocopherol concentration in plasma
of approximately 25 pmol per liter. Plasma tocopherol concentrations could be increased
only by 2-3 fold when subjects are fed high levels of a-tocopherol (Dimitrov et al., 1991;
Jialal et al., 1995). Studies have determined the underlying explanations for this
observation including variations in a-TTP activity, metabolic rate, lipid content and lipid
composition (Traber et al., 1998; Stahl et al., 1999; Roxborough et al., 2000).
In general, tocopherols are apparently concentrated wherever fatty acids
abundant, especially in structures of the cell containing phospholipid membranes, such as
mitochondria, and microsomes. The major total body pool of vitamin E is in adipose
tissue; however, it is not readily available to other tissues. The liver, instead, is a major
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repository when the intakes of tocopherols are high; therefore, the amount present in the
liver is considered an index of dietary intake (Jiang et al., 2001).
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Table 3. Comparison of Concentration of a- and y-Tocopherols in the Human
Plasma and Other Tissues

Plasma (pmol/L)
Adipose (nmol/g)
Muscle (nmol/g)
Skin (nmol/g)
(Jiang et al., 2001)

y- tocopherol
2-7
176 ±80
107
180 ±89

g-tocopherol
15-20
440 ± 279
155±163
127 ±74
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c. Degradation. Tocopherols are extensively metabolized before
excretion. Parker et al., 2000 reported that the degradation of tocopherols is by a
cytochrome P450 3-A (CYP3A) dependent process. This was proven by the inhibition of
y-CEHC formation by sesamin and ketoconazole, inhibitors of the CYP3 A family.
Therefore, clinical studies have suggested that drugs that interfere with metabolism of
CYP3 A system should be considered during vitamin E supplementation. Although the
involvement of CYP3 A in the degradation process of vitamin E is clear, a non CYP3A is
also responsible for tocopherol metabolism. The side effect of supranutritional dosages of
vitamin E may inhibit platelet aggregation. Thus it has been recommended that
anticoagulants and vitamin E supplements should not be provided simultaneously (Li et
al., 2001).
d. Antioxidant Properties. Most of the recent interest in the tocopherols
has focused on their antioxidant properties. The antioxidant activity of the tocopherols
and tocotrienols is believed mainly due to their ability to donate their phenolic hydrogens
to lipid free radicals. As a consequence, tocopherols are widely promoted to prevent or
modulate diseases that are supposedly associated with oxidative stress such as
cardiovascular disease, cancer, chronic inflammation and neurological disorders
(Christen et al., 1999; Ames et ah, 1993; Stephens et al., 1996).
The various tocopherols and tocotrienols inhibit lipid peroxidation in both foods
and biological systems. In biological systems, they function as chain breaking
antioxidants preventing propagation of free radical damage in plasma and in membranes
(Parrel et al., 1994; Rock et al., 1996). Chromanols react with both peroxyl and hydroxyl
radicals and are effective agents to prevent both internal and external oxidative stress.
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The chain-breaking antioxidant functions of vitamin E components results from their
close association with the polyunsaturated fatty acids (PUFA) found in the membranes.
Vitamin E is a potent peroxyl radical scavenger. When lipid hydroperoxides are
oxidized to peroxyl radicals (ROO ’), they react 1000 times faster with vitamin E than
with polyunsaturated fatty acids (RH). The hydroxyl group of tocopherol reacts with an
organic peroxyl radical, forming hydroperoxide (ROOM) and the tocopherol radical (Vit
E-0 ’) (Traber et al., 1999).
With vitamin E
ROO* + Vit E-OH

>

ROOH +

VitE-O*

Without vitamin E
>

ROO* + RH
R + 02

>

ROOH’ + R*

ROO*

Vitamin E, therefore, acts as a chain breaking antioxidant during propagation
phase, preventing the further autooxidation of lipids. The tocopheroxyl radical (Vit E-0 ’)
then reacts with vitamin C (hydrogen donors, AH) thereby oxidizing and returning
vitamin E to its reduced states.
VitE-O’ + AH

>

Vit E-OH + A*

The reducing agents, vitamin C, continuously repair oxidized tocopherol
preventing loss of it. The tocopheroxyl redical could also be reduced by glutathione, or
by membrane-bound quinols as well.
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Although all of the tocopherols are effective lipophilic antioxidants, y-tocopherol
provides a unique function. Because of an unsubstituted 5-position on the chromanol
ring, y-tocopherol could effectively remove reactive nitrogen species. (Christen, 1997)
The main membrane antioxidant tocopherols consists of two major forms, octocopherol and y-tocopherol, that differ structurally only by a methyl group substitution
at the 5-position. Gamma-tocopherol is the principal form of vitamin E in the diet,
whereas a-tocopherol is the more potent antioxidant and is the primary form in
supplements.
Study of general antioxidant properties of y-tocopherol suggest that accumulation
of y-tocopherol may be protective against both general oxidation reactions and nitrogen
dioxide (N02)-mediated damage. Animals are exposed to nitrogen oxides from a variety
of sources. Endogenous nitric oxide (NO) is produced by macrophages in response to
infection, by endothelial cells to control vascular tone, whereas a major exogenous
exposure to NO is cigarette smoke. Nitrogen dioxide is a known cause of mutation in
mammalian cells. Gamma tocopherol is a more potent inhibitor than a-tocopherol of
neoplastic transformation because of its superior ability to scavenge and chemically
reduce NO2 without forming a nitrosating intermediate.
e. Gamma-Tocopherol and Its Metabolite, y-CEHC, and Natriuretic
Activity. The natriuretic activity is involved in several diseases including hypertension
congestive heart failure and cirrhosis of the liver (de Wardener et al., 1961; Wecher et al.,
1990). It is the activity that inhibits extracellular volume expansion, which results in
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sustained natriuresis, elevating plasma concentration of a Na+ transport inhibitor and
pressor activity.
Recently, it has been shown that y-tocopherol was efficiently metabolized to
2,7,8-trimethyl-2-(p-carboxyethyl)-6-hydroxy chroman (S-y-CEHC, LLU-a), and S-yCEHC, which have been shown to exhibit a natriuretic activity. Moreover, it is found to
be the most potent natriuretic agents among tocopherol forms and the mechanism is via
inhibition of the 70 pS potassium channel in the apical membrane of the thick ascending
limb of the kidney, the assumed mechanism of action of the natriuretic hormone (Chiku
et al., 1984; Kantoci et al., 1997; Murray et al., 1997). Inhibition of this channel could
significantly block the recycling of potassium ion and thereby, inhibit the function of
Na+/ 2 C17K+ cotransporter, resulting in natriuresis (Wechter et al., 1996).
Moreover, study by Murray et al., 1997 demonstrated that a metabolized of a
minor component of the vitamin E complex, S-y-CEHC, obtained only through diet, is an
effector of the 70 pS potassium channel. The analogous compound derived from atocopherol was, on the other hand, completely inactive as a potassium channel inhibitor.
The investigators further investigated the biological mechanism by which y-tocopherol
may inhibit potassium channel. Since the antioxidant potential of an a-tocopherol is
greater than that of y-tocopherol, there is increased likelihood that the chroman ring of ytocopherol remains intact. The proposed side-chain oxidation without chroman ring
oxidized may be necessary for the production of an important regulator of the 70 pS
potassium channel and possibly in the regulation of extracellular fluid volume. These
findings suggested that the oxidative metabolite of y-tocopherol, (LLU-a, S-y-CEHC)
may be the source, all or in part, of helping modulate extracellular fluid volume in
28

mammals. In addition, the potassium channel inhibition taken together with the lack of
inhibition of sodium ion pump is consistent with the hypothesis that metabolite of ytocopherol is the putative natriuretic hormone (Takata et ah,2002).
There is a study underway to determine the concentration of LLU-oc in the urine
of pregnant woman, congestive heart failure, cirrhosis and head trauma patients and
volume-expanded states. If natriuretic activity were found, y-tocopherol metabolite would
be the second example of vitamin, after vitamin D, to act as a precursor for a hormone.
f Gamma-Tocopherol and Platelet Aggregation. Platelet aggregation
plays an important role in thrombosis and cardiovascular events (Conti et al., 1987;
Handin 1996). A number of epidemiologic studies, however, have demonstrated an
inverse association between CHD and vitamin E intake (Rimm et al., 1993; Stampfer et
al., 1993; Kushi et al., 1996). In contrast, there was no proven association from clinical
trial (Yusuf et al., 2000; GISSI 1999). Also not only is the association between
tocopherols intake and inhibition of platelet aggregation are inconsistent, but also the
biological mechanism by which tocopherols inhibit platelet aggregation is not completely
identified.
Saldeen et al., 1999 have designed a study to examine the differential effects of aand y-tocopherol on parameters of oxidation-antioxidation and thrombogenesis in rats.
They found that y-tocopherol supplementation led to a more potent decrease in platelet
aggregation and delay of arterial thrombogenesis than did a-tocopherol supplementation.
Moreover, both a- and y-tocopherol decreased arterial superoxide anion generation, lipid
peroxidation and LDL oxidation. In this experimental investigation, they concluded that a
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mixed tocopherol rich in y-tocopherol could decrease platelet aggregation and
intraarterial thrombus formation in rats.
In addition, Liu et ah, 2003, also reported the greater potency in preventing
platelet aggregation of mixed tocopherols than a-tocopherol alone in human. In this
study, participants were randomly assigned into three groups: a-tocopherol, mixed
tocopherol and control for 8 weeks. This study found that mixed tocopherol has a more
potent platelet inhibitory effect and that the cellular uptake of mixed tocopherol is higher
than those of a-tocopherol. The biological mechanism by which tocopherols inhibit
platelet aggregation is somewhat unclear. However, two of the proposed mechanism of
actions were related to nitric oxide (NO) bioactivity and inactivation of cellular protein
kinase C (PKC).
The first proposed biological mechanism is associated with increases in NO
release, activates of endothelial constitutive NO (ecNOS) synthase. Mixed tocopherols
were more potent in modulating NO release and ecNOS activation than a-tocopherol
alone. One of NO mechanisms of action is to reduce platelet recruitment to a growing
thrombus and inhibit platelet aggregation. Thus, reduced bioavailability of NO is an
indicator in patients with CAD and impaired of platelet NO production may predict acute
heart disease (Freedman et a., 1997, Freedman et al., 2000). Incorporation of tocopherol
into the diet has been found to increase platelet NO concentration by preventing it from
quenching by peroxyl radicals. Moreover, y-tocopherol is the potent activator of ecNOS
(Huie et al., 1993; Christen et al., 1997).
The other proposed mechanism by which tocopherols inhibit platelet aggregation
is thought to be through PKC mechanism. It was reported that intake of tocopherols
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resulted in a marked decrease in PKC activation by alterating its phosphorylation state
(Ricciarelli et ah, 1998; Freedman et ah, 1996).
In conclusion, mixed tocopherol may prevent platelet aggregation by increased
NO release, activating ecNOS and inhibiting PKC activation in platelets. Mixed
tocopherols have more potent effects on platelets aggregation than that of a-tocopherol
alone.
g. Gamma-Tocopherol and Inflammation. Antioxidant vitamins,
defending agents against oxidants produced during inflammation, are believed to play an
important role in public health and human disease prevention. Alpha-tocopherol, the
principal form of vitamin E in various tissues, have been extensively studied in vitro and
in vivo. In contrast, the data of y-tocopherol on the anti-inflammatory are scarce to date.
This is mostly due to its relatively low levels in plasma and tissue concentrations.
However, growing evidences indicates that y-tocopherol may be essential in the
defending mechanism against degenerative disease. Several investigators demonstrated
the inverse correlation between y-tocopherol and the incidence of inflammatory related
diseases.
Cooney et al.1993, reported the superiority of y-tocopherol to a-tocopherol in
trapping reactive nitrogen oxide species (NOx), mutagenic electrophiles generated during
inflammation. Nitrogen oxides could cause mutations in bacteria and mammalian cells
due to deamination of DNA. The end products of NOx species, nitrite and nitrate, may
contribute to chronic inflammation. Therefore, detoxification ability of y-tocopherol in
trapping NOx species and forming a more stable adduct, 5-nitro-y-tocopherol, is essential
in the prevention of inflammatory related diseases.
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Another in vivo study demonstrated the protective effects of y- and a-tocopherol
against peroxynitrite induced lipid peroxidation. This study found that lipid
hydroperoxide formation in liposomes exposed to peroxynitrite was inhibited more
effectively by y-tocopherol than a-tocopherol. In addition, y-tocopherol acts as a trap for
membrane soluble electrophilic nitrogen oxides and other electrophilic mutagens,
forming stable carbon-centered adducts through the nucleophilic 5-position (Christen et
al., 1997). This result supports the findings by Cooney et al. that y-tocopherol is superior
to a-tocopherol in trapping reactive nitrogen oxide species, mutagenic electrophiles
generated during inflammation because of the non substituted 5-position.
In addition to y-tocopherol reactivity toward reactive nitrogen oxide species, it
appears that y-tocopherol also plays a role in defending against inflammation-related
damage. Up to date, a few studies have investigated the effects of y-tocopherol on the
inflammatory response.
Jiang et al., 2000, studied the effects of y-tocopherol and inflammatory response
in macrophages and human epithelial cells after being exposed to COX-2-preinduced
cells by addition of arachidonic acids (AA). They found that y-tocopherol inhibited the
generation of prostaglandin E2 (PGE2), an important mediator synthesized via the
cyclooxygenase -2 (COX-2) during inflammation. Moreover, the major metabolite of ytocopherol (y-CEHC) also exhibited an inhibitory effect to PGE2 synthesis. However, ytocopherol required 8 to 24 hours incubation period to cause the inhibition, whereas, yCEHC required only an hour for the same reaction. These findings indicated that both ytocopherol and its major metabolite at physiological concentrations are effective in
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inhibiting COX-2 activity in intact cells, and possess anti-inflammatory activity. This
anti-inflammatory property is similar to those of NSAIDs.
In the study of carrageenan-induced inflammation in Wistar rats, administration
of y-tocopherol and y-CEHC significantly reduced PGE2 synthesis at the site of
inflammation. Gamma-tocopherol also inhibits leukotriene B4 (LTB4), another oxidized
product derived from AA through the 5-lipoxygenase -catalyzed pathway responsible for
inflammatory response. In addition to the inhibitory effects on the proinflammatory
eicosanoids, y-tocopherol administration reduced inflammation-mediated damage as
shown by reduced lipid peroxidation. Moreover, y-tocopherol appears to decrease TNFoc, a key proinflammatory cytokine known to activate macrophage and provoke the
inflammatory response (Jiang et al., 2003).
Collectively, y-tocopherol inhibits proinflammatory eicosanoids (PGE2 and
LTB4), and decreases level of an inflammatory cytokine, TNF-a, in a rat inflammation
model. These results strongly suggest that y-tocopherol shows anti-inflammatory
activities and may be essential for improving human inflammatory related diseases in the
future.
h. Gamma-Tocopherol and Disease
1. Gamma-Tocopherol and Heart Disease. There was limited
resources on y-tocopherol and heart disease, since most of the epidemiological evidence
observed the tocopherol as a whole. Majority of the data, therefore, has been presented as
vitamin E.
The correlation between consumption of fruits, vegetables and others foods
containing vitamin E and heart disease has been investigated in many studies.
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Consistently, coronary heart disease risk was inversely related to consumption of those
foods (Knekt et ah, 1994, Gaziano et al., 1995, Kushi et al., 1996). Observational studies
have further indicated that consumption of vitamin E more than 100 IU a day for greater
than two years may lower the rates of progression of coronary artery lesions and therefore
lower the rates of coronary events (Hodis et al., 1995)
Oxidized LDL could contribute to atherogenicity by many mechanisms including
increasing monocyte accumulation, reducing macrophage motility in the intima and
increasing cytotoxicity. Antioxidants, for instance vitamin E, is believed to attenuate
atherosclerosis by preventing oxidative modification of LDL, and increase the resistance
of LDL to oxidation. Oxidized LDL is taken up more rapidly than native LDL by
macrophages to create foam cells, leading cause of atherosclerosis lesions. Oxidized LDL
has also been identified as endothelial cells cytotoxic and may increase vasoconstriction
in arteries. The epidemiological results from the U.S. health professions both males and
females provided evidence of an association between a high intake of vitamin E and a
lower risk of coronary heart disease (Rimm et al., 1993, Stampfer et al., 1993).
Up to date, there have been four randomized, controlled trials of the correlation
between vitamin E and coronary heart disease; however, the results are inconsistent. In a
Chinese study, there was no significant reduction in cardiovascular events after 5.2 years
of vitamin E supplement 30 mg daily (Blot et al., 1993).
The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study (ATBC), also
demonstrated no effect on the risk of death from coronary heart disease of daily treatment
of 50 mg of vitamin E for 5-8 years (ATBC, 1994). Consistently, the results of a recent
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Italian trial demonstrated that supplemented vitamin E 300 IU daily did not alter the
number of patients with myocardial infarction significantly (GISSI, 1999).
In contrast to those interventional trials, Stephens et ah, 1996 reported a
tremendous reduction in the number of patients with nonfatal myocardial infarction
observed after receiving vitamin E 400 IU for 1.4 years. They also claimed that 400-800
IU of vitamin E supplement significantly reduced the incidence of cardiovascular death
and nonfatal myocardial infarction by 77%.
Ohrvall et al., 1996 conducted a cross-sectional study of tocopherols levels in
coronary heart disease patients compared to health age-matched reference participants.
They reported lower mean concentration of y-tocopherol and a higher ratio of a- to ytocopherol in coronary heart disease patients. These findings indicated a difference in
antioxidative status between coronary heart disease patients and healthy participants.
2. Gamma-Tocopherol and Cancer. Number of scientific
evidences suggested that low plasma levels of tocopherols might be used as a strong
predictor for incidence of cancer disease. In addition, y-tocopherol, is recently believed to
be effective anticancer agents with low cellular toxicity and also be beneficial in human
cancer disease prevention (Stone et al., 2004; Giovannucci 2000; Flohe et al., 1999).
Current epidemiological and experimental studies consistently suggest that y-tocopherol
may be superior to the commonly tested, a-tocopherol, as a cancer preventive.
In a nested case-control study, Helzlsouer et al., 2000, reported that men in the
highest quintile of plasma y-tocopherol concentration had a 5-fold reduced risk of
prostate cancer compared with those in the lowest quintile. They also found the
statistically significant protective associations of cancer and high levels of y-tocopherol.
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Given these data, y-tocopherol may be a better chemopreventive agent than a-tocopherol.
However, the use of combined a-tocopherol and y-tocopherol supplements for prostate
cancer prevention is still recommended due to the interaction between those two
tocopherol forms. The molecular mechanism behind the observed effect has not been
elucidated.
To discover the molecular anticancer mechanism of y-tocopherol, Gysin et al.,
2002, studied the human prostate carcinoma and colorectal adenocarcinoma. In this
study, y-tocopherol have been reported to inhibit cell cycle progression via reduction of
cyclin D1 and cyclin E levels. In addition, 2,7,8-trimethyl-2-((3-carboxyethyl)-6hydroxychroman, metabolites of y-tocopherol, shown to be more potent than atocopherol in inhibiting prostate cancer cell growth by the same mechanism as ytocopherol (Galli et al., 2004)
Jiang et al., 2004 found that y-tocopherol exhibited antiproliferation effect on
prostate cancer cells by inducing apoptosis in androgen-sensitive LNCaP. This effect of
y-tocopherol was partially reversed by the addition of arachidonic acid or linoleic acid,
the substrates for cyclooxygenase and lipoxygenase.
The cohort study, the alpha-tocopherol, beta-carotene cancer prevention (ATBC),
reported that participants with higher circulating concentrations of the major vitamin E
fractions, a- and y-tocopherols, had lower prostate cancer risk. In addition, incidence of
prostate cancer risk was reduced by 32% in response to daily a-tocopherol
supplementation (Weinstein et al., 2005).
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Vitamin E and other antioxidants are believed to prevent colon cancer by
decreasing the formation of mutagens generated from free radical oxidation. Therefore,
Stone et ah, 2004, conducted the study of chemopreventive potential of different forms of
vitamin E on colon cancer cell lines in both animal and human models. They found that
vitamin E levels in feces, colonocytes, plasma and liver were higher in rats fed with atocopherol supplementation. Moreover, compared to a-tocopherol, y-tocopherol was
found to be a more potent enhancer of proliferators-activated receptor-y, an effective
chemopreventive agents in a rat model of carcinogenesis. Similarly, Campbell et al., 2003
also reported the protective effect of y-tocopherol by upregulating the expression of
intracellular concentrations of peroxisome proliferators activated receptor-y. This ability
of y-tocopherol in colonic tissue may be relevant to colon cancer prevention.
2. Fatty Acids
a. Fatty Acid Composition of the Diet and of Walnuts. Walnuts have a
unique fatty acids composition containing ample quantities of the n-3 fatty acids, alinolenic acids (18:3, n-3, ALA). Values per lOOg edible portion are palmitic (16:0)
4.40g, stearic (18:0) 1.66g, oleic (18:1) 8.80g, linoleic (18:2) 38.10g and a-linolenic
(18:3) 9.08g.
The predominant polyunsaturated fatty acids in diets, especially western diets are
n-6 fatty acids. When the amount of n-3 fatty acids in the diet increases, they will replace
some of the n-6 fatty acids in membranes of cells such as monocytes, lymphocytes,
granulocytes and other cells.
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The fatty acids of membranes serve as precursors for the in vivo synthesis of
eicosanoids which in turn modulate inflammation and immunity. Both the level of fat in
the diet and the types of fatty acids present in the diet can affect the function of
lymphocytes and other immune cells.
Competition between n-6 and n-3 fatty acids occurs in prostaglandin formation.
Eicosapentaenoic acid (EPA), an n-3 fatty acid, competes with arachidonic acids, an n-6
fatty acids, for prostaglandin and leukotriene synthesis at the cyclooxygenase and
lipoxygenase level. Studies have shown that the ingestion of fish or fish oils containing
n-3 fatty acids leads to a decrease in leukotriene before formation.
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Linoleic acid (18:2,n-6)

a-Linolenic acid (18:3,n-3)

y-Linoleic acid (18:3,n-6)

Stearidonic acid (18:4,n-3)

Arachidinic acid (20:4, n-6)

Eicosatetraenoic acid (20:4,n-3)
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Proinflammatory lipid mediators

^
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Eicosapentaenoic acid (20:5,n-3)

(PEG2, LTB4, TXA2)
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Proinflammatory peptide mediators
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(TNF-a, IL-1B)

Pharmaceutical inhibitors and
mononuclear antibodies

Figure 3. Common molecular targets for anti-inflammatory therapies of the dietary
n-3 fatty acids and pharmaceuticals.
(adapted from James et ah, 2000)
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b. The Immune Response and Cytokines. Cytokines are regulatory
proteins secreted by white blood cells and a variety of other cells in the body; the
pleiotropic actions of cytokines include numerous effects on cells of the immune system
and modulation of inflammatory responses (Tumball et ah, 1999).
Cytokines are large (8-60 kDa), soluble polypeptide mediators that regulate
growth, differentiation and function of many cell types in both host defense and normal
and abnormal homeostatic mechanisms. Thus they have vital roles in haematopoiesis,
inflammatory responses and the development and maintenance of immune responses.
Furthermore, many cytokines may also induce fever, sleep, anorexia, malaise and
alterations in neuroendocrine secretions (Townsend et ah, 2000; Barrett 1996; Lucey et al
1996). They may be classified on the basis of their cell of origin, their spectrum of
activity, the category of activity they influence, the cells that they target, or on the
specific features of their ligan-receptor interaction, however, their classification remain
somewhat arbitrary. Most commonly, cytokines have been classified into families of
interleukins (IL), tumor necrosis factors (TNF), interferons (IFN), chemokines,
hematopoietin and colony-stimulating factors (CSF). As mentioned above, many
cytokines are overlapping in their actions therefore they could belong to more than one
family.
The difference in nature of the threat, i.e. bacterial, viral and inflammation to
tissue homeostasis result in diverse production of particular cytokines response.
Cytokine production increases significantly during cell disturbance. During cellular
challenges such as tissue remodeling, disease, infection or trauma, cytokines are
drastically produced. Not only could the nature of the threat, but also the type of tissue
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being provoked and the hormone milieu possibly determines the amount and type of
cytokine synthesis.
The regulation of inflammation by cytokines is intricate due to the fact that the
immune system has redundant pathways with multiple elements having similar
physiologic effects. For instance, one cytokine may fulfill a number of roles during
inflammatory reactions. Thus typical properties of cytokines are pleiotropy, redundancy,
synergistic activity and antagonistic effects upon each other (Barrett 1996; Opal et al.,
2000; Townsend et al., 2000). Disturbing the cytokines regulatory network either by
genetic, environment or foreign microbial may cause lethal consequences. The net effect
of any cytokines, however depend on the timing of cytokine release, the location in which
it acts, the presence of competing or synergistic elements, cytokine receptor density and
tissue responsiveness to each cytokine (Dinarello, 1998; Tumball et al., 1999;
Westendorp et al., 1997; Donnelly et al., 1996; Opal et al., 1996).
One of the physiological effects of cytokines disturbance is inflammation. It is
characterized symptomatically by pain, redness and swelling and excessive inflammation
entails loss of function. It is the process whereby blood cells and proteins enter tissues in
response to injury, infection, trauma or immune reaction.
There are two basic forms of inflammatory cytokines, proinflammatory and anti
inflammatory. Proinflammatory cytokines include IL-1, IL-6, IL-8, TNF-a and those
produced by Thlcells (IL-2 and gamma interferon). These cytokines favor the production
of inflammatory reactions. On the other hand, anti-inflammatory cytokines favor the
production of immunoglobulin E and activation and production of eosinophils and mast
cells. This includes IL-1 antagonist, transforming growth factor-P and those produced by
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Th-2 cells (IL-4, IL-5, IL-10). An imbalance of proinflammatory and anti-inflammatory
cytokines could cause inflammatory or allergic diseases (Lucey et al., 1996; Berguer et
al., 1999; Johnson et al., 2003; Kelley 2001).
Inflammation mechanism has been recognized to play a central role in mediating
all phases of atherosclerosis, from initial recruitment of circulating leukocytes to the
arterial wall to eventual rupture of vulnerable atherosclerotic plaque. Accordingly,
numbers of evidence has been compiled suggesting that markers of inflammation are
strong predictors of cardiovascular diseases such as myocardial infarction and stroke
(Blake at al., 2002; Pradhan et al., 2002; Hwang et al., 1997; Ridker et al., 1998).
Among the key inflammatory mediators are the n-6 eicosanoids, prostaglandin
(PGE) and leukotriene (LTB). Also important are the cytokines, interleukin-1, and tumor
necrosis factor (TNF). Under normal physiological circumstances, these cytokines and
eicosanoids serve as immuno-modulators that confine or sustain the potential injury of
inflammatory reactions. Under the pathological circumstance that these cytokines either
provide ineffective control over proinflammatory activities or overcompensate and inhibit
immune response, leaves the body at risk from systematic infections (Manoz et al., 1991;
Kasai et al., 1997; Fitzpatrick et al., 2001).
1. Interleukin-1 ft. IL-1 includes two distinct proteins, IL-la and
IL-ip that play vital roles in acute and chronic inflammation, both locally and
systematically. IL-lp is produced primarily by monocytes and macrophages, yet also by
astrocytes, oligodendroglia, adrenal cortical cells, NK cells, endothelial cells,
keratinocytes, megakaryocytes, platelets, neurons, neutrophils, osteoblasts, trophoblasts,
T cells and fibroblasts. It elicits many biological responses including thymocyte
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proliferation, fever reduction, wound healing and tissue resorption (Ito el al., 1996;
Hunter et al., 1995).
In female rats, IL-1 induces a variety of behavioral, neurochemical and
physiological effects including fever, suppression of food and water intake, condition of
taste aversion, reduced social exploration and reduced sexual behavior (Sung et al..
2002).

IL-1 (3, the most potent proinflammatory cytokines, has been proved to be a potent
stimulator of anxiogenic actions, and induces stress and anxiety-like behavior in rodents.
This cytokine activates the hypothalamus to release corticotrophin-releasing factor
(CRT), which induces the secretion of glucocorticoids from the adrenal. It also activates
CNS thereby increasing the turnover of noradrenaline, serotonin and dopamine (Connor
et al., 1998; Lacosta et al., 1998).
There is concrete knowledge that the immune system and CNS form a complex
interacting network. It is certain that there is a communication between the aspects of
immune system, endocrine system and CNS. Thus immune activation may provoke
neuroendocrine and central nervous system (CNS). In fact activating the immune system
may affect endocrine and transmitter processes and may influence some of the behavioral
effects (Song et al., 1999; Elenkov et al., 2000; Song 2000; Maier et al., 1998).
Studies of the immune response effects on cognitive function discovered that
induction of IL-1 p might cause brain inflammation and lead to cognitive impairment. In
patients with Alzheimer’s disease and other neurodegenerative diseases, increase in IL-lp
and other proinflammatory cytokines have been associated with cognitive impairment
(Licastro et al., 2000; Kalaria et al., 1996).
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Interleukin-1 is involved in activation of hypothalamus-pituitary-adrenal (HPA)
axis and neurotransmitter in several studies. Increasing secretion of corticosterone,
reduced release of acetylcholine and increasing metabolites of serotonin and dopamine in
the hippocampus and other limbic regions of the brain are related to IL-1 concentration.
In addition, systemic administration of IL-1 (3 could induce brain inflammatory response
and the expression of amyloid precursor protein (Oitzl et al., 1993; Gibertini et al., 1995;
Potter et al., 2001; Dunn 2000).
Even though concentrations of IL-1 is strongly related to cognitive impairment,
the most extensive study about the IL-1 is associated to their potent initiation of
inflammation. The physiological action of IL-1 is subsequent to various cells being
attacked by bacterial endotoxin or varieties of non-microbial inflammatory substances.
After threatening actions, IL-1 would be released with excessive quantities to the
circulation and trigger a general inflammatory response.
In a general inflammatory response, circulating IL-1 could function by inducing
capillary endothelial cells to secrete chemokines and increasing expression of cell
adhesion molecules (i.e. E-selectin, ICAM-1 and VCAM-1). Those chemokines and
adhesion molecules would further activate mononuclear cell integrins and facilitate
mononuclear infiltration into the area. Together with IL-2, IL-1 induces NK cells to
release interferon (IFN-y), resulting in IFN-y-induced activation of macrophages (Hunter
et al., 1995)
In addition, IL-1 regulated matrix metalloproteinases (MMPs), which could
initiate extracellular matrix degradation, monocytes migration, embryo implantation,
tissue involution, angiogenesis and wound healing. It is generally accepted that elevated
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levels of IL-1 is the key mediator that enhances the biosynthesis and secretion of MMPs.
Thus, the promotion of wound healing and tissue degradation is considered to be in part
due to IL-1 stimulated cells. Thus, suppression of IL-1 synthesis and activity is the most
effective strategy to control physiological inflammatory response (Ito et ah, 1996; Sica et
ah, 1990).
2. Interleukin-6. IL-6, like IL-1, is a proinflammatory cytokine
released from activated macrophages. It has, however, less extensive function in terms of
behavior, neurotransmitter and endocrine activity than those involving in IL-1. IL-6 was
originally identified as a B cell differentiation factor (Akira et ah, 1990)
IL-6 is a multifunctional protein synthesized by lymphoid and non-lymphoid
cells. It could also be generated by normal and transformed cells including T cells,
monocytes, macrophages, fibroblasts, hepatocytes, vascular endothelial cells, cardiac
myxomas, bladder cell carcinomas and myelomas. And because of its various functions,
IL-6 has also been known as IFN-|32, B-cell stimulatory factor-2 (BSF-2), hybridoma/
plasmacytoma growth factor and macrophage-granulocyte inducing factor 2A (MGA2A). It could be regulated either positively or negatively by a variety of signals and other
cytokines including mitogens, antigenic stimulation, lipopolysaccharides, IL-1, TNF, and
viruses (Breen et ah, 1990; Hirano et ah, 1984; Honda et ah, 1992).
The effects of IL-6 on different cells are abundant and diverse. On B-cells, it
encourages the differentiation and secretion of antibody. It also acts as a co-stimulant
triggering IL-2 synthesis and IL-2 receptor expression (Honda et ah, 1990; Kikutani et
ah, 1985). In addition, it also exhibits growth factor activity for mature thymic or
peripheral T-cells and enhances the differentiation of cytotoxic T-cells in the presence of
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IL-2 or IFN-y. On hepatocytes, IL-6 enhances production of acute phase proteins and
stimulates activity of hemopoietic stem cells. Additional bioactivities attributed to IL-6
include: inhibition of the growth and induction of terminal differentiation of myeloid
leukemic cells, induction of neuronal cell differentiation and induction of the maturation
of megakaryocytes (Haegeman et al., 1986; Okada et ah, 1983; Kikutani et al., 1985).
The various physiological effects of IL-6 mentioned above suggest that it has a major role
in the mediation of the inflammatory and immune responses initiated by infection and
injury (Kurzrock et al., 1993; Akira et al., 1990; Liu et al., 1992).
3. Tumor Necrosis Factor-a. TNF-a is also known as cachectin,
postulated to mediate wasting during chronic infections. It is produced by activated T and
B lymphocytes, neutrophils, astrocytes endothelial cells, smooth muscle cells and some
other transformed cells. For the last decade its bioactivities have been investigated by
numerous reviews. Most of those reviews propose the ability of activate multiple signal
transduction pathways to induce or suppress the expression of a vast number of genes,
including those for growth factors and cytokines, transcription factors, inflammatory
mediators and acute phase proteins (Vilcek et al., 1991; Aggarwal et al., 1984; Seckinger
et al., 1989; Narachi et al., 1987).
Engelmann et al., 1990 reported its effect on cells functioning in a number of
ways including defending against infectious agents and recovering from injury. Thus one
of the critical roles of TNF-a is to support normal host defense against infections and
against growth of malignat tumors. In particular circumstance, some of these effects may
become unfavorable, causing more harm than the pathogen itself. Seckkinger et al., 1989
stated that TNF-a could cause hemorrhagic necrosis of the tumors and cytotoxic effect in
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certain cell lines during pathological stage. In addition, it stimulates production of IL-1,
with which it share several biological activities. Together with IL-1, it could promote
collagenase production of human dermal fibroblasts and induce fever by stimulating
hypothalamic prostaglandins synthesis. Thus many studies projected that many of its
bioactivities functionally resemble the effects produced by IL-1.
Vilcek et al., 1991 reported that elevated levels of TNF-a could affect a number
of pathological conditions including cachexia, septic shock following gram negative
bacteria and autoimmune disorders. In fact, its overproduction could lead to severe
systematic toxicity and even death. It also has been implicated in the pathogenesis of
some autoimmune disorders and of graft-versus host defense (Aggarwal et al., 1984; Sica
et al., 1990).
4. E-Selectin. The selectin family consists of three closely related
cell-surface molecules with differential expression by leukocytes (L-selectin), platelets
(P-selectin) and vascular endothelium (E and P-selectin). The selectins function is
restricted to leukocyte interactions with vascular endothelium (Dong et al., 1998; McEver
1994). P and E selectins are adhesion molecules mediating the first step in leukocyte
extravasations.
At the site of tissue injury and inflammation, selectin mediates the initial
attachment of leukocytes to venular endothelial cells before their firm adhesion. Multiple
studies indicated that selectins mediate neutrophil, monocyte and lymphocyte rolling
along the venular wall (Lobb et al., 1991; Weller et al., 1991; Gearing et al., 1992).
E-selectin also known as endothelial Leukocyte Adhesion Molecule-1, expressed
only on endothelial cells and only after activation by inflammatory cytokines (IL-1 (3,
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TNF-a) or endotoxin (Bevilacqua et al., 1993; Kansas 1996). Like other selectins, Eselectin is a mediator of the rolling attachment of leukocytes to the endothelial cells, an
essential step in extravasation of leukocytes at the site of inflammation, thereby playing a
major role in localized inflammatory response. Expression of E-selectin is transitory,
reaching a maximum within approximately six hours of stimulation and then declining
with shedding of soluble E-selectin in circulation (Guray et al., 2004; Kansas
1996;Gearing et al., 1992). Elevated level of E-selectin in serum has been reported in a
variety of pathological conditions.
Up to date, there is increasing evidence that suggests that E-selectin contributes to
tumor growth and metastasis. It may promote tumoral angiogenesis and the adhesion of
tumoral cells in endothelial cells at distant sites (Makker et al., 2002; Hebbar et al.,
1998).
5. C-Reactive Protein. C-reactive protein (CRP) is an acute phase
protein with a well known association with infection and other inflammatory conditions.
It is the prototype of acute-phase proteins in humans and is widely used as a gauge for the
presence and extent of systematic inflammation (Ridker et al., 1998; Lopez et al., 2004;
Ridger et al., 2002).
The normal serum level of CRP is approximately less than 1 pg/ml yet can be
elevated as much as 1000 fold within 2-3 days after onset of acute inflammation
(Torzewski et al., 2000; Heuertz et al., 1994). The fact that it could be dramatically
increased and highly conserved throughout evaluation indicates its major physiological
function.
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CRP is essential in modulating a number of inflammatory and immune responses
and localizes to sites of inflammation in association with neutrophils. Study has shown
that CRP inhibits neutrophil chemotaxis to C5a in vitro (Robey et al., 1987). The
chemotaxis effect of CRP on monocyte/macrophage however is controversial. One report
demonstrated the effect of CRP on the stimulation of human monocyte chemotaxis and
procoagulant activity (Whisler et al., 1986). Nevertheless, another study has shown that
no effect on monocyte chemotaxis (Robey et al., 1987).
c. Fatty Acids and the Immune Response. Simopoulos 2002 reported that,
20-25 fold more of n-6 fats than n-3 fats were consumed in the typical western diet.
According to Continuing Survey of Foods Intakes by Individuals, CSFII (1994-1996),
however, reported current US dietary intake of linoleic acids, LA (18:2, n-6) to alinolenic acids, ALA (18:3, n-3) is 9.5:1, where as the current recommendation is 5:1.
This predominance of n-6 fats is suspected due to their abundant proportion in the diet.
N-3 PUFA is believed to be potent modulators of lymphocyte, monocyte,
macrophage, neutrophil and endothelial function and thus modulates immune and
inflammatory responses. Thus, in the past 15 year, many studies have investigated the
effect of n-3 PUFA on human immune and inflammatory responses. Simopoulos 2002,
reported that among the fatty acids, n-3 PUFAs is the most potent immuno-modulator. In
fact, n-3 PUFA modulates the amount and type of eicosanoids made and controls
intracellular signaling pathways, transcription factor activity and gene expression.
The effect of fish oil supplementation on the production of monocyte cytokines
was examined in a number of studies. Such studies have shown that n-3 PUFA can
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diminish peripheral blood mononuclear cell proliferation and reduce the production of
IL-2, IL-1, IL-6, TNF-a and interferon.
In 1989, Endres et ah, investigated the influences of n-3 PUFA on production of
TNF-a and IL-ip. Nine healthy volunteers incorporated fish oil concentrate into their diet
for six months. Production of IL-1 (3 and TNF-a were inhibited by 40 % and 61%
respectively
Meydani et al., 1991 reported that n-3 PUFA supplementation inhibited
proinflammatory cytokines synthesis in young and old women differently. There were
48% and 90% inhibition of IL-1 p synthesis in young and older women respectively.
There was 58% inhibition of TNF-a synthesis in young and 70% in older women. The
study further concluded that n-3 PUFA supplementation reduced cytokine production in
young women but inhibited T cells mitogenesis in older women.
Caughey et al., 1996 studied the effect of n-3 PUFA on TNF-a and IL-1 p synthesis in
twenty eight healthy volunteers. For the first four weeks of a flaxseed oil diet
consumption, TNF-a and IL-lp synthesis were inhibited by approximately 30%. Fish oil
diet continued for another four weeks, inhibited TNF-a and IL-lp synthesis by 74% and
80% respectively. They concluded that vegetable oil could also demonstrate inhibition of
proinflammatory cytokines yet in lesser extent. Table 4.
In a cross-sectional study of 727 women from the Nurses’ Health Study, n-3
PUFA was inversely associated with the levels of IL-6 in healthy women. IL-6 level was
23% lower among those in the highest quintile of n-3 PUFA compared with the lowest
quintile (Garcia et al., 2004).
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Table 4. The Inhibition of IL-1, IL-6, and TNF-a Production After n-3 PUFA
Consumption
References

Caughey et ak,
1996
Meydani et al.,
1991
Endres et al.,
1989
Kremer et al.,
1990

Subjects

Weeks
Daily amount of
of
n-3 PUFA
consumption
consumption

28 healthy

8

6 healthy
(23-33y)
6 healthy
(51-68y)
9 healthy

12

20 RA
patients
17 RA
patients

1.62 gEPA,
1.08 gDHA
1.68 gEPA,
0.72 g DMA
1.68 gEPA,
0.72 g DHA
2.7 g EPA,
1.8 gDHA
27 mg EPA,
18 mg DHA/kg
54 mg EPA,
36 mg DHA/kg

12
6
24
24

(James et al., 2000)
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% inhibition

EL-ip
78-81

TNF-a
70-78

48

58

90

70

61

40

40.6

n/a

54.7

n/a

In a double-blind cross-over study of hypercholesterolemia individuals, IL-6 and
TNF-a were significantly higher after consumption of a stick margarine diet compared to
a soybean oil diet. The ratio of total cholesterol to HDL-C was positively related to IL-1(3
and TNF-a production. The study concluded that a diet high in hydrogenated fat
increases inflammatory cytokines production and may lead to pathophysiology of
atherosclerosis (Han et al., 2002).
In animal studies, feeding laboratory animals a fish oil diet also resulted in
markedly decreased production of IL-1, IL-6 and TNF-a by inflammatory macrophages.
Song et al., 2003 evaluated the effect of an n-3 fatty acids (EPA) supplemented diet on
the stress/anxiety behavior in rats, which were induced by IL-1 (3 administration. They
discovered that EPA supplemented diet could reduce the elevated prostaglandins E2
secretion and increased secretion of IL-10. In addition, an EPA supplemented diet
attenuated IL-1 {3 function of reducing growth rate to a great extent. They concluded that
EPA supplemented diet appears to antagonize the endrocrine, immune, and behavioral
effects of IL-1 p administration.
In 2004 Song et al., compared the inflammation-induced impairment of spatial
memory in rats consuming coconut oil, soybean oil and EPA diets. After administering of
IL-1, serum corticosterone was increased, and spatial memory deficits were observed. IL1 p also caused an increase in the hippocampal prostaglandin E2 concentration. These
effects of 11-1 administration were attenuated in the group of rats that consumed the EPA
diet.
Foitzik et al., 2002 have studied the effects of n-3 fatty acid supplemented diet on
inflammatory cytokines in laboratory animal induced pancreatitis. They reported that
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infusion of n-3 fatty acids increases anti-inflammatory cytokines. In fact EPA-derived
mediators generated from n-3 fatty acids were less active or even exhibit anti
inflammatory effects in pancreatitis.
It is believed that induction in endothelial cells of adhesion molecules for
circulating leukocytes and of inflammatory mediators by cytokines probably contributes
to the early phases of inflammation. The proposed mechanisms by which dietary fatty
acids can modulate inflammation however are limited.
Yasunori et al., 1998 investigated the effect of triglyceride reduction on cell
adhesion molecules (sCAM) levels and E-selectin in twenty seven diabetic patients. To
test the hypothesis that triglyceride could modulate e-selectin concentration, n-3 fatty
acids (Omacor) have been given to patients at 4 g/d. After 7 months of supplementation,
the results show that triglyceride level was reduced by 47 ± 4.6% and soluble E-selectin
level was decreased by 16±3.2%. The researchers, thus, concluded that triglycerides and
HDL metabolism influence CAM expression. In addition, treatment with n-3 fatty acids
may alter vascular cell activation through inhibition of adhesion of monocytes.
Incorporation of DHA into cellular lipids may decrease expression of endothelial
leukocyte adhesion molecules, secretion of inflammatory mediators and leukocyte
adhesion to cultured endothelial cells. In fact, DHA controlled cytokine-stimulated
endothelial cell expression of E-selectin (Caterina et al., 1994).
In addition, in 727 women from Nurses’ Health Study I, the intake of ALA was
inversely associated with plasma concentrations of E-selectin (p=-0.24) after controlling
for age, BMI, physical activity, smoking status, alcohol consumption and intake of LA.
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E-selectin level was 10% lower among those in the highest quintile of total n-3 PUFA
consumption, compared with the lowest quintile (Garcia et ah, 2004).
In 2003, Pischon investigated habitual n-3 PUFA intake and its interaction with
n-6 PUFA in relation to the plasma inflammatory marker CRP among healthy 405 men
and 454 women. The results show that after adjusting for other predictors of
inflammation, intake of EPA and DHA was somewhat inversely associated with plasma
levels of CRP.
In a cross-sectional study of 727 women from Nurses’ Health Study, CRP level
was 29% lower among those in highest quintile of total n-3 PUFA, compared with the
lowest quintile. In fact, after adjusting for age, BMI, physical activity, smoking status,
alcohol consumption and intake of LA, the intake of ALA was inversely related to
plasma concentration of CRP (p = -0.55) (Garcia et al., 2004).
Besides consumption of n-3 PUFA, dietary fiber also influences plasma level of
CRP. Ajani et al., 2004 examined the association between dietary fiber and serum
concentration of CRP using data from the National Health and Nutrition Examination
Survey 1999-2000. The odds ratio (OR) for increased CRP concentration was 0.49 for the
highest quintile of fiber intake compared with the lowest intake.
Moreover, a randomized crossover design, compared the effect of trans fatty acid
to carbohydrate on CRP concentrations. Eight percent of fat was replaced by trans fatty
acids in diet of 50 men. After a 5 week period, CRP concentration was not statistically
significantly higher after consumption of the trans fatty acids than after consumption of
the carbohydrate diet (Baer et al., 2004).
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In conclusion, n-3 fatty acids in the diet can suppress the production of
inflammatory mediators including TNF-oc, IL-lp and IL-6. The mechanism responsible
for the suppression of these proinflammatory cytokines production by n-3 fatty acids
remains unclear, although suppression of eicosanoid production may be involved. Many
anti-inflammatory pharmacotherapies are intended for inhibiting the production of these
cytokines thus incorporate n-3 dietary fatty acids to diet may be beneficial.
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CHAPTER 3
METHODS
A. Subjects and Recruitment
Subjects for the study were individuals selected from those who participated in
the Walnuts Feeding Trial conducted by Joan Sabate and colleagues at the Department of
Nutrition, School of Public Health, Loma Linda University.
Subjects for the Walnuts Feeding Trial were recruited from Loma Linda
community and neighboring regions. Local publications, flyers and radio were utilized
for recruitment purposes at local companies and institutions. Subjects were recruited by a
multi-stage process. First, interested persons completed a preliminary questionnaire via
phone or email. Second, select group was invited to a group informational meeting.
During the meeting, purposes, procedure and requirement of the study were explained to
the potential subjects. Third, those interested in participating were further interviewed
individually following the meeting. Each subject received an explanation and signed an
informed consent before filling out medical and lifestyle questionnaires.
All eligible subjects were scheduled to classify information and to evaluate
perception of compliance for metabolic feeding study. Distance from Loma Linda
University, work schedule and reason of interest in the studied were investigated. The
study was approved by the Institutional Review Broad of Loma Linda University.
Admission into the study was based on following medical/biological criteria.
Subjects between the ages of 30-70, with no significant weight changes during previous
six months, not over or under weight, non-diabetic, and no known allergy to nuts were
considered. Subjects were also required to have their habitual diet closely related to the
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typical American diet with no nut consumption less than once per week. One hundred
and eleven subjects began the study. Ninety completed the trial.
Eighty subjects who had good compliance to their diet and who had their blood
draw completed at 4, 6, 10 and 12 month were selected for tocopherol analysis.
Thirty subjects who had the highest compliance to their diet by incorporating
walnuts into their diet more than 10% of daily energy intake according to the dietary
recall data, no anti inflammatory or other related medication use reported were selected
for proinflammatory markers analysis.
B. Protocol
The Walnut Feeding Trial was a 12-month randomized crossover intervention
study, which consisted of two phases, treatment and control. Ninety healthy adults
participated in this study. They were randomly assigned to either of these two phases for
the first six months and then switched to the other phase for the second six months.
During the treatment phase, participants volunteered to incorporate a portion of walnuts
equal to 12% of their daily energy intake (range 28 grams to 56 grams per day) in their
habitual diet. During the control phase, they followed their habitual diet. No other dietary
advice was given to either group.
C. Study Diet
Subjects were randomly assigned to start with either habitual diet (control phase)
or walnut supplemented diet (treatment phase). During control phase, subjects consumed
their usual diet for six month. Subjects were instructed to consume walnuts equal to 12%
of daily energy intake per day for six months for treatment phase. Walnuts were provided
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at time of clinic visits. No instructions as to time of the day or whether included in
cooked food were concerned.
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Figure 1. The study design
Note:
Habitual diet: usual diet
Walnuts diet: habitual diet + walnuts 12% of energy intake
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D. Data Collection
Subjects were required to maintain their activities, exercise and other lifestyle
habits. Any signs of illness experienced and, or supplements or medications ingested
were recorded by the investigators.
Blood specimens of each participant were obtained periodically at 4, 6, 10 and 12
months. The process of venipuncture followed the standard protocols of blood clinics.
The blood specimens were stored frozen at -80 degree Celsius until analysis at the
Nutrition Laboratory, Department of Nutrition, School of Public Health.
1. Plasma Tocopherols Analysis
Plasma samples were examined for tocopherols by High Performance
Liquid Chromatography (HPLC) method, utilizing a Normal Phase diol column as
described by Kramer et al., 1997. Solvents were HPLC grade isopropyl alcohol and
hexane UV. The tocopherols: alpha, beta, gamma, and delta were used as standards. The
extraction of tocopherols consist of pipetting 400 microliters of plasma and 400
microliters of ethanol, mix for 30 seconds. Four hundred microliters of hexane containing
4 microgram per milliliter of internal standard and 600 microliters of hexane containing
BHT were added, vortexed for 2 minutes and then centrifuged for 10 minutes at 2800
rpm. The hexane layers were removed (about 600 microliters) and evaporated to dryness.
Samples were reconstituted with 200 microliters of hexane, mixed well and then
analyzed for tocopherol fractions. Ten microliters of samples were injected, and then run
for a 20-minute cycle. Serum samples were tested in duplicate and averages were taken
for alpha, beta, gamma and delta tocopherol fractions.
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2. Plasma Inflammatory Mediators Analysis
Plasma concentrations of interleukin 1 beta (IL-lp), interleukin 6 (IL-6),
tumor necrosis factor alpha (TNF-a), and sE-Selectin were analyzed by utilizing the
quantitative high sensitivity technique in kit form according to the supplier’s instructions
(R&D Systems, Minneapolis, MN). C-Reactive Protein (CRP) was analyzed by utilizing
the ACTIVE US CRP Enzyme-Linked Immunosorbent Assay (ELISA) kit form
according to the supplier’s instructions (Diagnostic Systems Laboratories, Inc., Webster,
TX).
The absorbances of IL-1(3, IL-6, TNF-a, sE-selectin and CRP (measured in optical
density units) were determined with an automated spectrophotometer plate reader. The
absorbance, then were directly proportional to the amount of cytokine in the standard or
sample, and be converted to concentration by utilizing a standard curve.
a. Interleukin-1 p. The quantitative determination of human IL-lp
concentrations in plasma employs the quantitative sandwich enzyme immunoassay
technique. A monoclonal antibody specific for IL-ip has been pre-coated onto a
microplate. Standards and samples were pipetted into the wells in duplicate and any IL1 p present was bound by the immobilized antibody. After washing any unbound
antibody-enzyme reagent, a substrate solution was added to the wells and color
developed in proportion to the amount of IL-lp bound in the initial step. The color
development was stopped and the intensity of the color was measured with an automated
spectrophotometer plate reader set at 450nm. (R&D Systems, Minneapolis, MN)
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b. Interleukin-6, The quantitative determination of human IL-6
concentrations in plasma employed the quantitative sandwich enzyme immunoassay
technique. A monoclonal antibody specific for IL-6 has been pre-coated onto a
microplate. Standards and samples were pipetted into the wells in duplicate and any IL-6
present was bound by the immobilized antibody. After washing away any unbound
substances, an enzyme-liked polyclonal antibody specific for IL-6 was added to the wells.
Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution
was added to the wells and color develops in proportion to the amount of IL-6 bound in
the initial step. The color development was stopped and the intensity of the color was
measured with an automate spectrophotometer plate reader set at 450nm. (R&D Systems,
Minneapolis, MN)
c. Tumor Necrosis Factor-a. The quantitative determination of human
TNF-a in plasma employed the quantitative sandwich enzyme immunoassay technique. A
monoclonal antibody specific for TNF-a has been pre-coated onto a microplate.
Standards and samples were pipetted into the wells in duplicate and any TNF-a present
was bound by the immobilized antibody. After washing away any unbound substances,
an enzyme-like polyclonal antibody specific for TNF-a was added to the wells.
Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution
was added to the wells. After an incubation period, an amplifier solution was added to the
wells and color developed in proportion to the amount of TNF-a bound in the initial step.
The color development was stopped and the intensity of the color was measured with an
automated spectrophotometer plate reader set at 490nm. (R&D Systems, Minneapolis,
MN)
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d. E-Selectin. The quantitative determination of human soluble E-selectin
in plasma employs the quantitative sandwich enzyme immunoassay technique. A
monoclonal antibody specific for sE-selectin has been pre-coated onto a microplate.
Standards, samples, controls and conjugate were pipetted into the wells in duplicate and
any sE-selectin present was sandwiched by the immobilized antibody and a second
enzyme-linked monoclonal antibody specific for sE-selectin. Following a wash to remove
any unbound substances and/ or antibody-enzyme reagent, a substrate solution was added
to the wells and color developed in proportion to the amount of sE-selectin bound. The
color development was stopped and the intensity of the color was measured with an
automated spectrophotometer plate reader set at 450nm. (R&D Systems, Minneapolis,
MN)
e. C-Reactive Protein. The determination of CRP in plasma employs the
ACTIVE US CRP ELISA. This is an enzymatically amplified “two-step” sandwich-type
immunoassay. Standards, controls and samples were incubated in duplicate in
micropipette wells which had been coated with anti-US CRP antibody. After incubation
and washing, the wells were treated with another anti US CRP detection antibody labeled
with the enzyme horseradish peroxidase (HRP). After a second incubation and washing
step, the wells were incubated with substrate tetramethylbenzidine (TMB). An acidic
stopping solution was then added and the degree of enzymatic turnover of the substrate
was determined by dual wavelength absorbance measurement at 450 and 620 nm.
The absorbance measured was directly proportional to the concentration of US
CRP present. A set of US CRP standards was used to plot a standard curve of absorbance
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versus US CRP concentration from which the US CRP concentrations in the specimens
can be calculated. (Diagnostic Systems Laboratory, Inc., Webster TX)
E. Statistical Analyses
1. Plasma Tocopherols and C-Reactive Protein
Statistical analyses were performed with SAS software for windows
(version 8; SAS Institute, Cary NC). Descriptive statistics are expressed as means, and
standard deviations. Blood tocopherol and CRP data were normalized by logtransformation prior to analysis. Dietary treatments effects on blood cholesterol,
tocopherol and CRP variables were estimated by using mixed linear models, which
included a random factor for the subjects, a fixed factor for the diet period, and a fixed
factor representing the diet.
Univariate relations between log-CRP on the control diet, body mass index
(BMI), gender, usage of non steroids anti-inflammatory drugs (NSAIDs), usage of lipid
lowering medications and usage of vitamin E supplements were analyzed by a mixed
linear (variance components) model which included a fixed factor for the subject
characteristics of interest and a random factor for the subject. For this analysis data from
the 4th and 6th month of the habitual diet were treated as replicate. To test the interaction
between diet, vitamin E supplement usage, plasma ratios of tocopherols to cholesterol,
and CRP concentrations, a main effect term for a- or y- tocopherol to cholesterol ratio
and a term for interaction between a- or y- tocopherol and diet were added to the model.
The a- and y- tocopherol to cholesterol ratios were treated as dichotomous variables
based on the median on the control diet.
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Results from all mixed linear models are presented in original units after back
transformation, and are presented as least-square geometric means, % difference and 95%
confidence intervals.
Multiple linear regression was used to examine the combined effect of dietary
plus supplemental a-tocopherol, dietary y-tocopherol, gender, age, BMI and usage of
NSAIDs in subjects on their habitual diets and on the walnut-supplemented diet. Models
were constructed using stepwise variables selection and Mellows’ C criterion. Both
procedure led to the same models.
2. Plasma Inflammatory Mediators
The effect of walnuts on proinflammatory cytokines including E-Selectin,
IL-ip, IL-6, and TNF-oc was examined by mixed-effect models, with fixed-effect terms
for diet and period. Although the data was correlated, the correlations did not markedly
decline over time, and therefore the covariance structures were modeled using compound
symmetry model. In addition, gender-diet interactions were tested by adding appropriate
fixed terms to the model. Correlation analysis was employed to check for possible
relations between each of the proinflammatory cytokines and serum tocopherols. All
outcome and tocopherol values were normalized by log transformation prior to analysis.
However, for ease of interpretation, final results were presented in original units.
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Introduction
The results of epidemiological studies have shown a correlation between nut
consumption and reduced incidence of cardiovascular disease (1-3). Several clinical trials
have shown that the consumption of nuts has favorable effects on serum lipid profiles
with a decrease in total- and low density lipoprotein (LDL) - cholesterol as well as
triglycerides (4-6). These clinical findings explain only part of the cardiovascular disease
(CVD) risk reduction observed in the epidemiologic outcomes, suggesting that nuts might
have antiatherosclerotic effects beyond blood lipid lowering.
For years the main cause of atherosclerosis was assumed to be the accumulation
of lipids in the arterial wall. More recently, a body of evidence has been compiled which
suggests that markers of inflammation are strong predictors of cardiovascular events
including stroke, peripheral artery disease and myocardial infarction (7-10). These
markers include proinflammatory cytokines and acute phase proteins especially Creactive protein (CRP). Dietary factors that affect low-level systemic inflammation are
those that inhibit lipid oxidation such as tocopherols, and vitamin C and the n-3
polyunsaturated fatty acids (n-3 PUFA) (11-14).
Walnuts are a rich source of y- tocopherol (20.83 mg/ 100 g edible portion),
which is an important lipophilic antioxidant. In cell systems and animal studies, ytocopherol was more potent than a-tocopherol with respect to inhibition of
cyclooxygenase and reduction of eicosanoids and inflammatory damage (15-17).
Walnuts are one of the few plant foods which contain high concentrations of the
n-3 PUFA, a-linolenic acid (ALA). The amounts of ALA in a handful of walnuts (28 g)
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is approroximately 5 times the daily intake in the US diet. N-3 PUFA have been shown to
have anti-inflammatory and antiatherogenic effects (18-19).
The aim of this present study was to determine whether concentrations of a-, ytocopherols and CRP in plasma are affected by the addition of walnuts to the diet of
healthy individuals. We also investigated the association between walnuts intake, vitamin
E supplement use and CRP levels.
Subjects and Methods
Study Population
This study was conducted in 80 healthy persons (33 men and 47 women) aged 3072y recruited from employees of Loma Linda University and residents of the surrounding
community through payroll inserts, flyers, and newspaper advertisements. The basis for
this work was a study designed to determine the effect of a daily walnut supplement on
body weight and composition. The study protocol, consent form, and subject-related
materials were approved by the Institutional Review Board of Loma Linda University.
Written informed consent was obtained from all subjects.
Eligibility criteria were that participants had to have no significant weight
changes during the previous six months, a BMI<35, a habitual diet close to the typical
American diet, and infrequent nut consumption (i.e., less than once a week). Excluded
were individuals with a diagnosed metabolic disorder that could affect body weight (i.e.,
diabetes, hypothyroidism) and those with an aversion to or a known allergy to nuts.
Except for fish oil and n-3 polyunsaturated fatty acid containing supplements, subjects
were not required to discontinue taking their usual medications and dietary supplements.
Subjects were asked to maintain their usual activities and lifestyle habits.
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An initial structured interview with each participant provided information about
usual medication and dietary supplement use. This information was validated by data
obtained through the periodic 24-hour dietary recalls which were conducted throughout
the study.
Experimental Protocol
The study was a randomized crossover field trial which lasted for 1 year and
included two 6-month diet periods: the habitual diet of the participants; and the habitual
diet plus a walnut supplement. At baseline, participants were randomly assigned to one of
two treatment sequences. In the first sequence participants consumed their habitual diet
plus a walnut supplement for six consecutive months then switched to their habitual diet
for six consecutive months; and, in the second sequence participants started out with their
habitual diet for six consecutive months and then switched to the walnut-supplemented
diet for six consecutive months. Figure 1
Study Diet
The walnut supplement consisted of a quantity of walnuts that provided
approximately 12% of the daily energy intake. Initial allotment of walnuts was based on
projected daily energy expenditure computed using the World Health Organization’s
published equations. In subsequent clinic visits, the walnut allotment was adjusted based
on the actual daily energy intake as reported by the participants in the 24-hour recalls.
Shelled walnuts were provided in labeled packets, one for each day of the week in
amounts varying from 28g to 56g and distributed every two months. Subjects were
requested to return any unconsumed portion.
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Dietary Recalls
To ascertain compliance with study requirements 24-hour dietary recalls were
obtained through telephone interviews by trained nutritionists using the Nutrition Data
Systems for Research (Nutrition Coordinating Center, University of Minnesota, 2000).
Telephone interviews were unannounced and obtained on non-consecutive days. Seven
recalls were collected during each diet period for a total of 14 recalls for the study. To
capture daily variations in intake, 2 weekend days and five weekdays were covered by
the seven recalls.
Laboratory Analyses
Fasting (12 hour) blood specimens were obtained at baseline and at the end of
months 4, 6, 10 and 12. After an overnight fast, blood was collected by venipuncture into
evacuated tubes with heparin as anticoagulant. Blood specimens were centrifuged at 1200
x g at 4° C for 10 minutes, portioned and stored at -80° C for subsequent analysis.
Blood lipids were measured by conventional enzymatic methods. Plasma
tocopherol concentrations were measured by high performance liquid chromatography
(HPLC) using a normal phase diol column (Supelco, Bellefonte, PA) and the method of
Kramer et al (19) C-reactive protein was measured by a commercial high sensitivity
ELISA kit (Diagnostic Systems Laboratories, Webster, TX).
Statistical Analyses
Statistical analyses were performed with SAS software for windows (version 8;
SAS Institute, Cary NC). Descriptive statistics are expressed as means, and standard
deviations. Blood tocopherol and CRP data were normalized by log-transformation prior
to analysis. Dietary treatments effects on blood cholesterol, tocopherol and CRP variables
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were estimated by using mixed linear models, which included a random factor for the
subjects, a fixed factor for the diet period, and a fixed factor representing the diet.
Univariate relations between log-CRP on the control diet, body mass index
(BMI), gender, usage of non steroids anti-inflammatory drugs (NSAIDs), usage of lipid
lowering medications and usage of vitamin E supplements were analyzed by a mixed
linear (variance components) model which included a fixed factor for the subject
characteristics of interest and a random factor for the subject. For this analysis data from
the 4 and 6 month of the habitual diet were treated as replicate. To test the interaction
between diet, vitamin E supplement usage, plasma ratios of tocopherols to cholesterol,
and CRP concentrations, a main effect term for a- or y- tocopherol to cholesterol ratio
and a term for interaction between a- or y- tocopherol and diet were added to the model.
The a- and y- tocopherol to cholesterol ratios were treated as dichotomous variables
based on the median on the control diet.
Results from all mixed linear models are presented in original units after back
transformation, and are presented as least-square geometric means, % difference and 95%
confidence intervals.
Multiple linear regression was used to examine the combined effect of dietary
plus supplemental a-tocopherol, dietary y-tocopherol, gender, age, BMI and usage of
NSAIDs in subjects on their habitual diets and on the walnut-supplemented diet. Models
were constructed using stepwise variables selection and Mellows’ C criterion. Both
procedure led to the same models.
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Results
Baseline characteristics of study participants are shown in Table 1. Use of
vitamin E supplements was common among the study participants with 21 individuals
taking a separate vitamin E supplement, this not including those taking multivitaminminerals supplements which contain lower doses of the vitamin.
As shown in Table 2, total cholesterol levels were significantly lower on the
walnut supplemented diet in all subjects and in users of vitamin E supplements. Although
the absolute concentrations of oc-tocopherol in plasma were lower on the walnut diet, the
lipid-adjusted molar ratio of a-tocopherol to total cholesterol did not change. The molar
ratio of y-tocopherol to cholesterol was significantly higher on the walnut supplemented
diet. Mean CRP levels did not significantly differ on the walnut diet in those who did not
use vitamin E supplements. However, there was a significant interaction between CRP
concentrations, use of vitamin E supplements and the walnut supplemented diet. Blood
CRP concentrations were substantially lower among users of vitamin E supplements and
the levels increased on the walnut diet in this subgroup.
Table 3 presents the results of the univariate models. CRP was significantly lower
for users of NSAIDs and vitamin E supplements than for non-users. CRP was nonsignificantly higher in females than in males and non-significantly lower in users of lipid
lowering drugs than in non-users with only 3 participants in this category. There was no
relation between age and CRP, but BMI was linearly related to log (CRP) ((3=0.088 ±
0.029, p=0.002) as shown in Figure 2.
The interaction between the walnut-supplemented diet, blood levels of atocopherol and y-tocopherol and CRP are shown in Figures 3 and 4. Exploratory
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analysis indicated no relation between absolute amounts of a- or y-tocopherol to CRP
levels. However, there was an interaction between the ratios of these nutrients to total
blood cholesterol level and CRP concentration. The ratios of a- and y- tocopherol to
cholesterol were treated as dichotomous variables based on the median of the control diet.
CRP levels were significantly higher on the walnut-supplemented diet but only among
those with a high ratio of a-tocopherol to cholesterol and a low ratio of y-tocopherol to
cholesterol.
Results of the multiple linear regression analysis are shown in Table 4. During
both on the habitual diet and the walnut-supplemented diet, BMI was positively
associated with, and dietary a-tocoherol from food and supplements, dietary ytocopherol, and use of NSAIDs were negatively associated with blood CRP
concentrations.
Discussion
In this 12-month randomized crossover field trial we examined the effects of daily
walnut intake on plasma tocopherol and CRP concentrations. Walnuts were provided
raw, shelled, and in individualized portions calculated to provide 12% of daily energy
intake. Subjects were randomly assigned to two treatment sequences: either to adhere to
their habitual diet for six months followed by their habitual diet plus walnuts for the next
six months; or, to consume their habitual diet plus walnuts for six months followed by a
six month period of their habitual diet. Subjects were not asked to make any changes in
their usual diet, medication or dietary supplement use.
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Walnuts are a concentrated source of y-tocopherol and although the unadjusted
levels of y-tocopherol were not different on the walnut diet, walnut consumption resulted
in lower plasma lipids and a significantly higher ratio of y-tocopherol to cholesterol.
Tocopherols in blood are associated with lipoproteins and the molar ratio of
tocopherol to cholesterol better reflects status (20). Unlike oc-tocopherol, y-tocopherol is
not maintained in the blood and large increases in intake are reflected in relatively small
changes in plasma levels. It is now known that a-tocopherol and y-tocopherol are equally
well absorbed and secreted by the intestine into chylomicron lipoprotein (21-22).
However, a-tocopherol is preferentially secreted by the liver into nascent very-lowdensity lipoprotein via a cytosolic liver tocopherol-binding protein. (23). RRR-atocopherol has a greater affinity for this tocopherol-binding protein than RRR-ytocopherol. The tocopherol binding protein is the major determinant of plasma tocopherol
levels. The concentration of y-tocopherol in tissues such as coronary endothelial cells
may be higher than that of plasma as tissues receive y-tocopherol from chylomicrons
(24). Walnuts contain practically no a-tocopherol and blood concentration of atocopherol were lower on the walnut diet. However, the ratios of a-tocopherol to
cholesterol did not differ between the diets which indicates that nutrient status with
respect to a-tocopherol was not compromised on the walnut diet.
Vitamin E supplement users exhibited higher levels of a- and lower levels of ytocopherol than nonusers both on the habitual and on the walnut diet. This has been
observed in other studies (16, 24-25). It is likely that supplementation with a-tocopherol

74

displaces y-tocopherol from the hepatic tocopherol-binding protein thus depressing the
levels of y-tocopherol in plasma.
There has been an increasing interest in the role of y-tocopherol in disease
prevention (26-27). Both a- and y-tocopherol are potent lipophilic antioxidants and ytocopherol uniquely scavenges reactive nitrogen species (15). Gamma-tocopherol is more
potent than oc-tocopherol with respect to inhibition of cyclooxygenase in cell systems and
in decreasing proinflammatory eicosanoids and inflammation damage in rats (17).
Also, y-tocopherol was shown to significantly attenuate oxidized LDL mediated
activation of transcription factor NF-kB pathway and apoptosis in human coronary artery
endothelial cells (28).
The clinical implications of blood y-tocopherol levels are not clear. Some studies
show that decreases in plasma y-tocopherol are associated with atherosclerosis and heart
disease (29-30) whereas others do not support a protective effect (27).
In addition to being a source of y-tocopherol, walnuts are also one of the richest
plant sources of the n-3 fatty acid alpha-linolenic acid. There is some evidence showing
that n-3 fatty acids may have anti-inflammatory effects. Supplementation with n-3 fatty
acids has been reported to inhibit mononuclear cell proliferation and monocyte cytokine
production (13). The question we attempted to answer was whether walnut consumption
would have an anti-inflammatory effect as reflected in blood levels of CRP. Recently,
CRP has been identified as a marker of systemic inflammation and associated with
increased risk of cardiovascular disease, myocardial infarction and stroke (7).
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Walnut consumption did not influence CRP levels among non users of vitamin E
supplement. However, the walnut diet resulted in significantly higher CRP levels in
vitamin E supplement users. The determinants of CRP levels in our subjects were
consistent with those found by other researchers. CRP levels were positively associated
with BMI and negatively associated with NSAIDs use and vitamin E supplement use.
To determine whether the observed increase in CRP levels on the walnut diet may
be related to alterations in plasma a- and y-tocopherol, the association between plasma
CRP levels and the ratios of a- and y-tocopherol to cholesterol was examined. As shown
in Figures 3 and 4, CRP levels were higher on the walnut diet but only in those with a
high ratio of a- and a low ratio y-tocopherol to cholesterol respectively. Regular use of
vitamin E supplements is expected to increase the ratio of a-tocopherol to cholesterol
and to decrease the ratios of y-tocopherol to cholesterol. Why CRP levels were higher on
the walnut diet in vitamin E supplement users and in those with higher blood levels of atocopherol and lower blood levels of y-tocopherol is not clear.
Multiple regression models with CRP as the outcome variable show that both
dietary a-tocopherol intake from food plus supplements and dietary y-tocopherol intake
are negatively associated with plasma CRP on both the habitual diet and the walnut diet.
This indicates that dietary intake of both a- and y- tocopherol modulate CRP levels.
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TABLE 1. Characteristics of the Participants at Baseline1

Male

Female

(n = 40)

(n = 50)

Age (y)

53.13±11.77 55.38±9.65

BMI (kg/m2)

27.49±2.59

25.36±3.93

Total cholesterol (mg/dL) 221.21±36.01227.75±33.42
Vitamin E supplement

i

Users

7

9

Non-users

33

41

Mean ± SD
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TABLE 2. Serum Cholesterol, a-, y- Tocopherols, Ratio of a-, y- Tocopherols to Cholesterol and C-reactive Protein for the Habitual and
Walnut Supplemented Diet
Habitaul diet
LS Mean1

Difference walnut minus habitual diet

Walnut diet

95% Cl2

LS Mean

% Diff

95% Cl

P-value

95% Cl

Interaction
P-Value

Total Cholesterol (mmol/L)
All subjects*

5.51

5.29

5.72

5.36

5.16

5.57

-2.62

-4.76

-0.44

0.0191

Vitamin E supplement non user

5.45

5.21

5.71

5.36

5.13

5.61

-1.62

-4.07

0.89

0.2035

Vitamin E supplement user*

5.74

5.34

6.18

5.34

4.96

5.75

-6.97

-11.21

-2.53

0.0032

33.761
31.019
47.137

30.973
28.338
39.211

36.803
33.956
56.664

32.308
29.995
42.586

29.64

35.219

-4.4

-7.2

-1.5

0.004

27.402
35.442

32.835

-3.3

-6.4

-0.1

0.0045

51.17

-9.7

-16.1

-2.7

0.008

0.0907

Alpha-tocopherol (pimole/L)
All subjects*
Vitamin E supplement non user*
Vitamin E supplement user*

0.101

Alpha-tocopherolxholesterol (pimole/mmole)

OO
to

All subjects

6.129

5.666

6.630

6.000

5.547

6.489

-2.1

-5.1

1

0.18

Vitamin E supplement non user

5.615

5.179

6.088

5.54

5.11

6.006

-1.3

-4.7

2.1

0.44

Vitamin E supplement user

8.615

7.304

10.162

8.096

6.872

9.539

-6.0

-13.0

1.5

0.11

All subjects

2.34

1.987

2.757

2.39

2.028

2.815

2.1

-4.3

8.9

0.529

Vitamin E supplement non user

2.736

2.301

3.254

2.789

2.345

3.317

1.9

-5

9.4

0.598

Vitamin E supplement user

1.303

0.919

1.848

1.344

0.948

1.903

3.1

-12.1

20.8

0.712

0.256

Gamma-tocopherol ((j.mole/L)

0.901

Gamma-tocopherolxholesterol (pmole/mmole)
All subjects*

0.428

0.360

0.510

0.459

0.386

0.547

7.2

0.4

14.5

0.04

Vitamin E supplement non user

0.512

0.427

0.616

0.538

0.448

0.646

5.0

-2.3

12.8

0.18

Vitamin E supplement user*

0.213

0.147

0.309

0.254

0.175

0.368

19.4

1.7

40.2

0.03

All subjects*

1585.6

1293.7

1943.3

1759.5

1436.5

2155.2

10.97

4.27

18.1

0.0011

Vitamin E supplement non user

2142.7

1731.5

2651.4

2150.0

1737.4

2660.5

0.34

-5.92

7.02

0.9173

1173.3

828.6

1661.5

1439.9

1018.2

2036.2

22.72

10.28

36.58

0.002

0.152

C-reactive protein (ng/ml)

Vitamin E supplement user*
'Least Square Mean
2 95% Confidence Interval

* Statistically siginificant different from habitual diet, p < 0.05

0.001

TABLE 3. CRP (ng/ml) Concentration of Participants by Gender, Usage of NSAIDs,
Usage of Vitamin E Supplement and Usage of Lipid Lowering Medications1
n

LS Mean2

95% Clz

Females

47

2065

1599

2668

Males

32

1567

1149

2137

+31.78%

-11.85%

+96.99%

P-value

Gender

Difference

0.176

NSAIDs
Users

21

1129

693

1839

Non-users

58

2206

1816

2682

-48.83%

-69.59%

-13.96

Difference

0.013

Vitamin E supplement
Users

21

1193

824

1726

Non-users

58

2165

1732

2703

-44.89%

-64.21%

-15.16%

Difference

0.007

Lipid lowering medications
Users

3

1013

366

2803

Non-users

76

1891

1545

2314

-46.42%

-81.02%

+51.19%

Difference

i

0.235

CRP concentration are of those obtained on the 4 and 6 month of the habitual diet
values are least-squares means and 95% confidence intervals
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TABLE 4. Multiple Linear Regression Results with CRP Levels Set As the
Dependent Variable and Dietary a-Tocopherol, Dietary y-Tocopherol, BMI and
NSAIDs Set As Independent Variables
Diet and model variables

Model

Standardized p

p-value

R2
Habitual Diet

< 0.0001

0.27

Dietary a-tocopherol

-0.29

0.005

Dietary y-tocopherol

-0.24

0.019

BMI

0.28

0.008

NSAIDs

-0.22

0.030

Walnuts Supplemented Diet

< 0.0001

0.24

Dietary a-tocopherol

-0.16

0.104

Dietary y-tocopherol

-0.26

0.015

BMI

0.28

0.009

NSAIDs

-0.27

0.010
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Habitual Diet

Walnut Supplemented Diet

Walnut Supplemented Diet

Habitual Diet

t
BD

t

t

BD

BD

Note:
Habitual diet: usual diet
Walnuts diet: usual diet + walnuts 12% of energy intake
FIGURE 1. The study design
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FIGURE 2. The relation between baseline BMI (kg/m2) and log (CRP) in
participants (p = 0.088 ± 0.029, p = 0.002)
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□ Habitual Diet H Walnuts Supplemented Diet
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FIGURE 3. Least-squares means and 95% confidence intervals of CRP
concentrations (ng/ml) in all participants with a high and low molar ratio of atocopherol to cholesterol on the habitual and walnuts supplemented diet
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FIGURE 4. Least-squares means and 95% confidence intervals of CRP
concentrations (ng/ml) in all participants with a high1 and low2 molar ratio of ytocopherol to cholesterol on the habitual and walnuts supplemented diet
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Introduction
The concept that food components offer benefits beyond basic nutrition is
relatively new to the scientific community. This knowledge continues to be supported by
research, which demonstrates that a health promoting diet is defined as much by foods
consumed as by those avoided.
The favorable metabolic outcomes of consuming walnuts is relatively novel and
thought to be due to a lipid composition low in saturated fatty acids (SFA) and high in
polyunsaturated fatty acids (PUTA). Although the nutrient contribution of walnuts is
similar to that of other tree nuts, it is distinguished by a high proportion of the n-3 fatty
acids and oc-linolenic acid (ALA, 18:3, n-3).
According to prospective cohort studies such as the Adventist Health Study, the
Nurses Health Study, the Iowa Woman’s Health Study and the Physician’s Health Study
more frequent nut consumption is correlated with cardiovascular risk reduction and is
inversely associated with all cause mortality (1-4). In addition, clinical human
intervention studies which involve adding walnuts to the diet are consistent in showing
decreases in total cholesterol and low density lipoprotein (LDL)-cholesterol (5-9).
Studies have shown that long term supplementation of capsules from fish oil
containing the long chain n-3 fatty acids eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) reduced production of proinflammatory mediators such as
interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor (TNF) in healthy
volunteers (10-13). The inhibition of IL-1, IL-6 and TNF production is accompanied by a
decreased ratio of arachidonic acid (AA) to EPA in the membrane phospholipids of
mononuclear cells (10). EPA can be formed endogenously from the 18-carbon fatty acid,
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a-linolenic acid, and foods containing n-3 fatty acids such as flaxseed oil and fish oil
have received more attention in nutrition research.
Nonetheless, the effect of walnuts, known as rich source of ALA, on
proinflammatory mediator synthesis has not yet been examined. There is as yet no
information regarding the association between walnuts ingestion, antioxidant status and
proinflammatory cytokines production. Therefore, the purpose of the present study is to
determine whether the addition of walnuts to the diet produces similar effects on
reduction of proinflammatory mediators and cytokines as those observed in fish and
flaxseed oil.
Subjects and Methods
Subjects
Subjects for this study were selected from participants in the walnut body weight
trial conducted by Joan Sabate and colleagues at the Department of Nutrition, School of
Public Health, Loma Linda University.
Eligibility criteria were no significant weight changes during previous six months,
not over or under weight, non-diabetic, and no known allergy to nuts. Subjects were also
requested to have their habitual diet closely related to the typical American diet with nuts
consumption less than once per week. Subjects were also required to maintain their
activities, exercise and other lifestyle habits throughout the study. Any signs of illness
experienced and, or supplements or medications ingested were recorded.
Thirty participants met eligibility criteria for the cytokines sub-study. Selected
subjects consumed no multivitamin, vitamin E, flax seed, fish oil supplements, no anti
inflammatory medications taken, no history of heart diseases and inflammatory related
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diseases reported, and established at least 10% of energy intake from walnuts during the
walnut supplemented diet phase as reflected in the 7 of 24 hour dietary recalls.
The Institutional Review Board of Loma Linda University approved the study.
Each subject received an explanation and signed an informed consent before being
included in the study.
Study Design
This was a 12-month randomized crossover intervention study, which consisted of
two phases, walnut supplemented diet phase and habitual diet phase. Subjects were
randomly assigned to either of these two phases for the first six months and then switched
to the other phase for the second six months. During the walnut supplemented diet phase,
subjects volunteered to incorporate a portion of walnuts equal to 12% of their daily
energy intake into their habitual diet. Subjects followed their habitual diet for habitual
diet phase. No other dietary advice was given to both phases. Figure 1
Prepackages daily allowances of raw, shelled walnuts were provided in amounts
varying from 28 to 56g, according to subjects’ total energy intake. No instructions as to
time of the day or cooking method were concerned.
The composition of walnuts was reviewed according to the United State
Department of Agricultural (USDA). One hundred gram of edible portion of walnuts
contain 6.126 g of total saturated fatty acids, 8.933 g of total monounsaturated fatty acids
(8.799 g of 18:1 and 0.134 of 20:1 isomers), 47.174 g of total polyunsaturated fatty acids
(38.093 g of 18:2, 9.080 g of 18:3 isomers).
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Blood specimens were collected at the end of month 4, 6, 10, and 12 for future
laboratory analyses. Compliance to the prescribed diet was ensured and assessed by 7
random 24-hour recall during each diet period.
Laboratory Analyses
After the subjects had fasted overnight, blood was collected by venipuncture into
evacuated tubes that were contained heparin as anticoagulant. Blood specimens then were
centrifuged at 2.7 x g for 10 min at 4 °C. The plasma was portioned and stored at -80 °C
for future laboratory analyses at nutrition department, School of Public Health Loma
Linda University.
The quantitative determination of human soluble E-Selectin, IL-ip, IL-6 and
TNF-ot were measured by an ultrasensitive ELISA (R&D Systems, Minneapolis).
Statistical Analyses
The effect of walnuts on proinflammatory cytokines including E-Selectin, IL-lp,
IL-6, and TNF-a was examined by mixed-effect models, with fixed-effect terms for diet
and period. Although the data was correlated, the correlations did not markedly decline
over time, and therefore the covariance structures were modeled using compound
symmetry model. In addition, gender-diet interactions were tested by adding appropriate
fixed terms to the model. Correlation analysis was employed to check for possible
relations between each of the proinflammatory cytokines and serum tocopherols. All
outcome and tocopherol values were normalized by log transformation prior to analysis.
However, for ease of interpretation, final results were presented in original units.
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Results
Blood specimens from thirty participants were analyzed for inflammatory
cytokines levels. No adverse effects due to the consumption of walnuts were observed or
reported. Participant’s baseline characteristics including age and BMI are shown in Table
1.
Least square means and 95% confidence intervals of e-selectin, TNF-a, IL-lp,
and IL-6 during habitual and walnuts supplemented diet are shown in Table 2. There
were no significant differences of the plasma e-selectin and TNF-a in the group as a
whole. Among female participants, e-selectin and TNF-a increased 3.91% and 5.74%
respectively on the walnut supplemented diet. In contrast, both inflammatory markers
decreased but not significantly among male participants on the walnut supplemented diet.
Plasma levels IL-lp and IL-6 were lower on the walnuts supplemented diet in the
combined group of male and female participants (p= 0.0015, p= 0.017, respectively).
However, in contrast with the other two inflammatory markers, plasma levels of IL-lp
and IL-6 significantly dropped only in the male group of participants Table 2.
Discussion
The anti-inflammatory effects of n-3 fatty acid have been extensively studied.
However, the effect of n-3 fatty acid on inflammation, atherosclerosis and the risk of
heart disease is somewhat controversial. In a healthy male population, Ascherio et al.,
(14) did not find a substantial reduction on the risk of coronary heart disease among
healthy men after increasing fish intake from one to two servings to five to six serving
per week. Furthermore, in the Physicians’ Health Study there was no evidence for an
association between dietary intake of fish and any cardiovascular endpoint (15).
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Moderate fish intake was not associated with a reduced risk of cardiovascular disease. In
contrast, Mori et al., found that supplementation of 3.65 g/d of n-3 fatty acids for 12
weeks significantly reduced platelet aggregation whereas, the GISSI-Prevenzione trial
suggested that 1 g/d of n-3 fatty acids reduced the risk of cardiovascular death in
myocardial infraction patients (16-17).
Regarding the anti-inflammatory effects of n-3 fatty acids, diets supplemented
with n-3 or n-6 fatty acids, or a combination of both exerted different effects on
inflammatory response, which is probably related to differing roles on the modulation of
inflammatory response. Supplementation of 4.5 g per day of n-3 fatty acids for 6 weeks
has been shown to suppress IL-lp, IL-la, IL-2 and TNF in healthy adults (18-19). In
contrast, Chan et al., documented the lack of effect of fish oil fed at a level of 4 g per day
on CRP, TNF and IL-6 in obese individuals after 6 weeks treatment (20).
In this study, we examined the relation between the consumption of walnuts rich
in ot-linolenic acid and plasma concentrations of biomarkers of inflammation among
healthy participants. Compared to habitual diet, there was no effect of walnuts
consumption on plasma concentrations of e-selectin and TNF-a. However, we found an
inverse relationship between walnuts consumption and plasma concentrations of IL-lp
and IL-6. IL-lp levels were 13.4% lower whereas, IL-6 levels were 16.06% lower during
walnuts supplemented diet. These associations were independent of lifestyle and
physiologically different since it was crossover design trial.
The relevance of inflammation in the atherogenic process was suggested recently
by several studies. For years, the main cause of atherosclerosis was thought to be the
accumulation of lipids in the arterial wall. However, there is growing evidence which
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suggests that markers of inflammation are strong predictors of cardiovascular disease
(21). These markers include the proinflammatory cytokines such as IL-6, TNF-a and IL1(3 and adhesion molecules such as e-selectin (21-25). It is suggested that oxidized low
density lipoprotein triggers a proinflammatory response and that IL-6 may have a major
role in the mediation of the inflammatory and immune responses initiated by oxidation
and injury (22-23). In addition, an association between proinflammatory cytokines
obesity and coronary heart disease has been demonstrated (24). Moreover, e-selectin, a
soluble cell adhesion molecule, increases after inflammation, and elevated e-selectin
levels are detected among coronary artery disease patients (25).
One plausible mechanism by which n-3 fatty acids modulate inflammation is by
lowering hydrogen peroxide production. Hydrogen peroxide is a major activator of the
nuclear factor-xB system, the coordinator of expression of adhesion molecules upon
cytokine stimulation. Multiple double bonds in the carbon structure of n-3 fatty acids
react first with active oxygen species thus sparing other molecules. This effect produces a
reduction in the amounts of hydrogen peroxide in the system (26-27).
In vitro studies demonstrated that the inhibitory effects of polyunsaturated fatty
acids on inflammation are different depending on the number of unsaturated double
bonds of n-3 fats. The ability to inhibit inflammation increases with the number of
unsaturations, and the carbon chain length is not a factor (26, 28). Thus, the most potent
inhibitor of the inflammation activation in vitro is the docosahexaenoic acids. However,
there is no confirmation about this plausible mechanism in any of in vivo study. Our
finding suggested that walnuts, rich in polyunsaturated fatty acids, had similar inverse
associations with some of the biomarker of inflammation, especially IL-lp and IL-6.
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The human body is capable of converting a portion of cc-linolenic acid to EPA or
DHA. This conversion is inefficient and depends on the quantity of n-6 and n-9 fatty
acids intake since these fatty acids compete with n-3 fatty acids for desaturase enzyme in
the synthetic pathway. Thus, the EPA and DHA, highly unsaturated fatty acids, are 2.5-5
times more effective in modulating inflammatory cytokines than a-linolenic acid. This
might explain the results of our findings of no alteration in plasma levels of TNF-a and eselectin. Moreover, the high content of the n-6 fatty acids, linoleic acids, in walnuts may
have inhibited the full effect of a-linolenic acid.
In conclusion, this study suggests that walnut consumption inversely associated
with inflammatory factors including IL-1(3 and IL-6, which may explain in part the
beneficial effect of nut consumption in lowering the risk of heart disease.
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TABLE 1 Baseline Characteristics of Participants

Age (y)
BMI

Male

Female

(n=12)

(n=18)

43±9.37

52.33±10.18

27.59±3.41

25.95±4.01
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TABLE 2
Least-squares Means and 95% Confidence Intervals of E-selectin, TNF-a, IL-lf, and IL-6 During Habitual and Walnut
Supplemented Diet
Walnuts supplemented diet

Habitual diet
LS Mean i
e-selectin (ng/mL)

TNF-a (ng/mL)

IL-6 (ng/mL)

IL-lp (ng/mL)

% Diff

95% Cl

p-value

95% Cl

35.56

51.77

43.33

35.91

52.28

1

-1.97

4.06

0.5117

Females

37.51

29.85

47.14

38.98

31.01

48.99

3.91

0.03

7.93

0.048

Males

49.07

36.08

66.73

48.17

35.43

65.5

-1.83

-6.24

2.8

0.4305

All subjects

1.107

0.988

1.241

1.13

1.008

1.267

2.106

-2.003

6.388

0.3182

1.15

1.001

1.321

1.216

1.058

1.397

5.738

0.333

11.434

0.0373

Males

1.066

0.884

1.284

1.051

0.872

1.266

-1.401

-7.441

5.033

0.6602

All subjects

1.841

1.382

2.451

1.545

1.16

2.058

-16.06

-24.57

-6.597

0.0015

Females

1.938

1.369

2.746

1.828

1.29

2.59

-5.713

-17.39

7.616

0.3812

Males

1.748

1.094

2.793

1.306

0.818

2.086

-25.28

-36.81

-11.65

0.0007

All subjects

0.333

0.29

0.383

0.289

0.25

0.333

-13.4

-22.9

-2.59

0.0168

Females

0.353

0.294

0.425

0.324

0.27

0.389

-8.25

-20.4

5.81

0.2346

0.251

0.394

0.257

0.203

0.327

-18.2

-32.6

-0.63

0.0431

0.314
Males
Squares Mean and 95% Confidence Intervals
TNF-a, tumor necrosis factor-a
IL-1P, interleukin-1 p
IL-6, interleukin-6

T Least

LS Mean

42.9

All subjects

Females

o

95% Cl i

% Difference

Habitual Diet

Walnut Supplemented Diet

Walnut Supplemented Diet

Habitual Diet

t
BD

t

t

BD

BD

Note:
Habitual diet: usual diet
Walnuts diet: habitual diet + walnuts 12% of energy intake
FIGURE 1. The study design
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CHAPTER 6
CONCLUSION
A. Summary and Implications of Findings
In this 12 month feeding trial study, we examined the relationship between long
term walnut consumption, rich in n-3 fatty acids and y-tocopherol, and plasma
concentrations of inflammatory mediators including IL-1(3, IL-6, e-selectin, TNF-a, and
CRP in healthy men and women participants.
Walnuts are an excellent source of y-tocopherol, however we found that
increasing the amount of walnuts in a diet insignificantly increased plasma y-tocopherol
concentration. In addition, oc-tocopherol level was significantly decreased as walnuts
supplemented for 12% of daily energy intake. The addition of walnuts of 28-56 g per day
into diet may have decreased the level of oc-tocopherol concentration. The mechanism by
which walnuts, rich in y-tocopherol, decreased the plasma concentration of oc-tocopherol
is unclear and need further investigation. One of the proposed mechanisms is the
competitive absorption rate of both tocopherols.
The fatty acid profiles of many nuts have been found to have beneficial effects.
Walnuts have a unique profile that is high in n-3 fatty acids, which have been shown to
have positive outcomes on the inflammatory related disease such as heart disease, and
cancer. The effects of long term walnuts consumption on the inflammatory mediators
were interesting. The findings proved that this amount of walnuts consumption may be a
benefit in inflammatory related diseases.
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B. Limitations
This study was an intervention study, thus was subject to difficulties in
controlling walnut consumption. Participants’ compliance was monitored. However,
given the length and scope of the trial it was often difficult for participants to comply
100% with the protocol. Moreover, multiple clinic visits were burdensome to participants
to complete. Several follow-up clinics were set up to minimize this limitation.
The amounts of the specimen were also one of the important limitations. Since the
analyses were conducted after the study had been completed, utilizing specimen for all
laboratory analysis was a concern.
C. Conclusions and Future Reserach
Incorporating walnuts as a regular part of the diet may be of concern in those who
take vitamin E supplement because of the interaction. The beneficial effects of vitamin E
supplement may be compromised by dietary walnuts intake. However, the biological
mechanism needs further investigation.
Comparison of n-3 fatty acids from walnuts and other high n-3 fatty acids foods
such as fish oil on the inflammatory effect would be an interesting study for the future.
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